Giovanni Martinelli

Giovanni Martinelli's AcademicInfluence.com Rankings

Giovanni Martinelli

Computer Science

#4038

World Rank

#4246

Historical Rank

Machine Learning

#674

World Rank

#684

Historical Rank

Artificial Intelligence

#877

World Rank

#893

Historical Rank

Database

#1276

World Rank

#1346

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Giovanni Martinelli's Degrees

PhD Computer Science University of Milan
Masters Computer Science University of Milan
Bachelors Computer Science University of Milan

Similar Degrees You Can Earn

Why Is Giovanni Martinelli Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Giovanni Martinelli's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) (1736)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. (2006) (1186)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. (2015) (888)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. (2016) (882)
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition (2006) (852)
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy (2004) (826)
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. (2009) (620)
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. (2019) (585)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. (2004) (582)
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. (2005) (567)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. (2000) (506)
Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia (2006) (504)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. (2011) (501)
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. (2001) (457)
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. (2003) (399)
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. (2003) (387)
Very young women (<35 years) with operable breast cancer: features of disease at presentation. (2002) (382)
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. (2011) (380)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. (2011) (364)
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. (2007) (359)
Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study (2017) (355)
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. (2011) (353)
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. (2009) (340)
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. (2007) (339)
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. (2009) (332)
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study (2003) (323)
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. (2001) (322)
Molecular Characterization of a Non–Babesia divergens Organism Causing Zoonotic Babesiosis in Europe (2003) (318)
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. (2010) (301)
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. (2002) (297)
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. (2009) (294)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. (2017) (292)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. (2008) (288)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia (2015) (270)
Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial (1998) (265)
Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. (2005) (252)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. (2019) (242)
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia (2015) (234)
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. (2010) (233)
N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? (2005) (228)
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). (2000) (228)
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). (2009) (223)
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. (2009) (221)
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study (2013) (211)
CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. (2002) (210)
Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma (2006) (208)
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. (2013) (202)
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. (2008) (200)
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. (2007) (199)
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. (2007) (199)
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. (2007) (197)
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. (2007) (197)
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. (2007) (194)
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase (2008) (194)
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. (2009) (189)
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study (2007) (186)
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study (2007) (186)
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. (2003) (185)
Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. (2001) (180)
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. (1996) (177)
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. (2018) (174)
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts (2007) (173)
IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. (2004) (171)
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. (2000) (171)
Angiogenic growth factors and endostatin in non‐Hodgkin's lymphoma (1999) (171)
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. (2011) (170)
The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. (2009) (169)
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. (2009) (168)
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. (2013) (166)
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. (2011) (164)
The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. (1987) (164)
A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. (2002) (163)
Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels (2020) (162)
Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity1 (2000) (162)
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. (2013) (159)
PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013) (2014) (157)
Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. (2006) (156)
Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation (2012) (154)
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. (2001) (152)
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). (2015) (150)
Pre–B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requires IKAROS function (2009) (144)
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. (2004) (142)
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (2016) (142)
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. (2007) (140)
Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. (2002) (140)
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. (2015) (137)
MDM2 inhibition: an important step forward in cancer therapy (2020) (136)
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy (2018) (135)
Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases (1999) (134)
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. (2014) (132)
Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. (2003) (129)
Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia (2012) (128)
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. (2003) (125)
Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. (1996) (123)
Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. (2004) (122)
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. (2011) (120)
Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. (2003) (120)
Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement (2014) (118)
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. (2008) (117)
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. (2012) (117)
Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. (1992) (116)
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. (2009) (116)
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells (2008) (115)
The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories (2011) (114)
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. (2018) (112)
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. (2011) (111)
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. (2017) (110)
The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance (2006) (109)
Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. (2015) (108)
GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. (2019) (106)
Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. (2005) (105)
Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients (2006) (105)
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. (2011) (104)
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS (2009) (102)
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. (2015) (102)
Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients (2016) (102)
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. (2009) (101)
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy (2013) (101)
Novel translocations that disrupt the platelet‐derived growth factor receptor β (PDGFRB) gene in BCR–ABL‐negative chronic myeloproliferative disorders (2003) (100)
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. (2004) (100)
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients (2006) (99)
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy (2008) (99)
Nuclear factor κB as a target for new drug development in myeloid malignancies (2007) (99)
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (2015) (98)
Identification of four new translocations involving FGFR1 in myeloid disorders (2001) (98)
Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. (2000) (98)
A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2 (2020) (98)
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes (2009) (98)
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (2001) (98)
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. (2011) (97)
Circulating endothelial cells as a novel marker of angiogenesis. (2003) (97)
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. (2008) (96)
Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. (2000) (96)
Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. (1998) (95)
Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. (2009) (94)
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia (2016) (93)
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. (2012) (93)
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up (2008) (93)
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications (2012) (93)
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion (2007) (91)
3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. (1999) (91)
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data (2016) (90)
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. (2004) (89)
Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (2000) (88)
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma (2012) (87)
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study (2010) (87)
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia (2005) (87)
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target (2020) (86)
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia (2013) (85)
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia (2020) (85)
Characteristics and outcome of therapy‐related myeloid neoplasms: Report from the Italian network on secondary leukemias (2015) (85)
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States (2016) (83)
Chronic myeloid leukemia stem cells (2019) (83)
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis (2011) (83)
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. (2007) (83)
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome‐positive adult acute lymphoblastic leukemia (2007) (82)
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). (2011) (82)
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. (2009) (81)
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. (2004) (79)
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation (2017) (78)
Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. (2006) (78)
New tyrosine kinase inhibitors in chronic myeloid leukemia. (2005) (77)
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway (2005) (76)
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up (2009) (75)
Generation and functional characterization of human dendritic cells derived from CD34+ cells mobilized into peripheral blood: comparison with bone marrow CD34+ cells (1998) (74)
Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts (2016) (74)
IKAROS Deletions Dictate a Unique Gene Expression Signature in Patients with Adult B-Cell Acute Lymphoblastic Leukemia (2012) (73)
Supplementary Figure S2 (2012) (73)
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. (2010) (73)
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib (2015) (73)
Chromothripsis in acute myeloid leukemia: biological features and impact on survival (2017) (72)
A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR (2014) (72)
Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. (2000) (72)
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients (2001) (71)
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. (2011) (71)
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. (2006) (71)
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. (2006) (71)
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase (2015) (71)
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial (2018) (71)
CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients (2011) (70)
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib (2012) (70)
Supplementary Figure S3 (2012) (69)
Assessing Tumor Angiogenesis (2004) (69)
Dissecting the role of aberrant DNA methylation in human leukemia (2015) (68)
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. (2009) (68)
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study (2002) (68)
Ifosfamide by continuous infusion to prevent encephalopathy (1990) (68)
Fludarabine‐containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients (1999) (68)
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. (2013) (68)
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients (2017) (67)
MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences (2018) (66)
Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML‐1107) (2012) (65)
Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas (2004) (65)
Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas (2004) (65)
Dual tyrosine kinase inhibitors in chronic myeloid leukemia (2005) (65)
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia (2012) (65)
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. (2006) (64)
Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen. (1998) (64)
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide (2014) (64)
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia (2016) (64)
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). (2014) (64)
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. (2008) (63)
Atypical juvenile polyposis (1981) (63)
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. (2011) (63)
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2017) (61)
Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes (2013) (61)
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies (2000) (61)
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial (2009) (60)
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis (2014) (59)
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome (2008) (59)
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia (2007) (58)
The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party (2010) (58)
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia (2008) (58)
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. (2015) (57)
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells (1999) (57)
Liposomal daunorubicin versus standard daunorubicin: long term follow‐up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia (2008) (57)
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. (2001) (57)
Aneuploidy: Cancer strength or vulnerability? (2018) (57)
Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts) (2014) (57)
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study. (2019) (57)
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. (2007) (56)
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma (2015) (56)
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. (2008) (56)
Differences among young adults, adults and elderly chronic myeloid leukemia patients. (2015) (56)
PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL. (2007) (56)
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. (2009) (56)
Prevalence of Achromobacter xylosoxidans in pulmonary mucosa‐associated lymphoid tissue lymphoma in different regions of Europe (2014) (56)
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. (2007) (56)
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma (2013) (55)
Genomic lesions associated with a different clinical outcome in diffuse large B‐Cell lymphoma treated with R‐CHOP‐21 (2010) (55)
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. (2008) (55)
High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment (2007) (54)
Phosphoinositide 3‐kinase/Akt inhibition increases arsenic trioxide‐induced apoptosis of acute promyelocytic and T‐cell leukaemias (2005) (54)
Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes. (2009) (53)
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis (2013) (53)
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. (2010) (52)
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. (2000) (52)
Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma (2000) (52)
Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants. (1992) (51)
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia (2014) (51)
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. (2011) (51)
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma (2014) (51)
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts. (2003) (51)
Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies (2011) (51)
Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML) (2013) (51)
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts. (2003) (51)
Supplementary Figure S4 (2012) (51)
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. (2016) (50)
Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment (2016) (50)
Cytogenetic and Molecular Predictors of Outcome in Acute Lymphocytic Leukemia: Recent Developments (2012) (50)
Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA) (2015) (50)
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia (2016) (50)
Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. (2014) (49)
Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations (2008) (48)
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients (2016) (48)
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. (1999) (48)
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (2019) (48)
Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐up (2015) (47)
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification (2015) (47)
Intrapericardial Treatment of Neoplastic Pericardial Effusions (2000) (47)
The cell cycle checkpoint inhibitors in the treatment of leukemias (2017) (47)
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. (2020) (47)
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀? (2011) (47)
CAR-T cell therapy: a potential new strategy against prostate cancer (2019) (46)
Endodermal sinus tumor arising in the endometrium. (1980) (46)
All-trans-retinoic acid and pseudotumor cerebri. (1996) (46)
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia (2019) (45)
High activity 90Y‐ibritumomab tiuxetan (Zevalin®) with peripheral blood progenitor cells support in patients with refractory/resistant B‐cell non‐Hodgkin lymphomas (2007) (45)
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. (2010) (45)
Imatinib mesylate for the treatment of chronic myeloid leukemia (2008) (45)
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients (2016) (44)
Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. (2010) (44)
Fournier’s gangrene: a clinical presentation of necrotizing fasciitis after bone marrow transplantation (1998) (44)
Multicentre phase III trial on fludarabine, cytarabine (Ara‐C), and idarubicin versus idarubicin, Ara‐C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients (2005) (44)
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). (2006) (44)
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients (2016) (44)
c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells (2011) (44)
Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome (2017) (44)
Multicentre phase III trial on fludarabine, cytarabine (Ara‐C), and idarubicin versus idarubicin, Ara‐C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients (2005) (44)
The transactivating isoforms of p63 are overexpressed in high‐grade follicular lymphomas independent of the occurrence of p63 gene amplification (2005) (43)
c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells (2011) (43)
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. (2004) (43)
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. (2013) (43)
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia (2019) (43)
The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase (2010) (43)
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial. (2004) (43)
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. (2004) (43)
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. (2007) (43)
Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry (2004) (43)
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. (2006) (43)
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. (2007) (43)
Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. (2002) (42)
Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. (2000) (42)
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model (2012) (42)
Best Practices in Chronic Myeloid Leukemia Monitoring and Management. (2016) (42)
Interferon-alfa for chronic myeloid leukemia. (2003) (42)
A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG) (2016) (42)
Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (2016) (42)
Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin (2020) (41)
Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study (2011) (41)
Malignant histiocytosis (true histiocytic lymphoma) clinicopathological study of 25 cases (1985) (41)
In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. (2002) (41)
Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL. (2007) (41)
Pulsed ATRA as single therapy restores long-term remission in PML-RARα-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study (2001) (41)
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management (2006) (40)
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery (2018) (40)
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia (2015) (40)
Apoptosis induction with three nucleoside analogs on freshly isolated B‐chronic lymphocytic leukemia cells (1994) (40)
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B‐cell lymphoma (2013) (39)
Advanced mast cell disease: an Italian Hematological Multicenter experience (2008) (39)
Advanced mast cell disease: an Italian Hematological Multicenter experience (2008) (39)
Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy (2000) (39)
Correlation of presence of granulomas with clinical and immunologic variables in Crohn's disease. (1988) (39)
Molecular Monitoring (2014) (38)
Totally implantable central venous access ports for high-dose chemotherapy administration and autologous stem cell transplantation: analysis of overall and septic complications in 68 cases using a single type of device (1999) (38)
Immunotherapy in Acute Myeloid Leukemia: Where We Stand (2021) (38)
Increased expression of myeloid antigen markers in adult acute lymphoblastic leukaemia patients: diagnostic and prognostic implications (1994) (38)
Chemotherapy during pregnancy: what is really safe? (2004) (38)
Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method (2008) (38)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). (2015) (37)
Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance. (2007) (37)
A new method of "in-cell reverse transcriptase-polymerase chain reaction" for the detection of BCR/ABL transcript in chronic myeloid leukemia patients. (1996) (37)
Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes (2011) (36)
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. (2008) (36)
S876 GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL (2019) (36)
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2019) (36)
Epithelioid leiomyoma of the breast with granular cell change: a case report. (1993) (36)
Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (2018) (36)
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. (2012) (35)
Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. (1998) (35)
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms (2010) (35)
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia (2021) (35)
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. (2003) (35)
e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants? (2005) (35)
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. (2020) (35)
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. (2010) (35)
Supplementary Table S2 (2012) (35)
Clinical activity of everolimus in relapsed/refractory marginal zone B‐cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (2014) (35)
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure (2009) (35)
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma (2017) (35)
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases (2008) (34)
Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). (2018) (34)
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients (2012) (34)
Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia (2006) (34)
Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response (2009) (34)
Line Treatment of Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Final Results of the GIMEMA LAL1205 Study (2008) (34)
Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non‐Hodgkin's lymphoma (2003) (33)
Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial (2018) (33)
Mast cell leukemia: a report of ten cases (2008) (33)
Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. (2011) (33)
Mast cell leukemia: a report of ten cases (2008) (33)
5’UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia (2017) (33)
Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis. (1998) (33)
Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross‐matching locally available platelet products (2004) (33)
Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study. (2006) (33)
Network integration of multi-tumour omics data suggests novel targeting strategies (2017) (33)
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' (2007) (32)
c‐Abl and Src‐family kinases cross‐talk in regulation of myeloid cell migration (2010) (32)
14‐3‐3 Ligand Prevents Nuclear Import of c‐ABL Protein in Chronic Myeloid Leukemia (2009) (32)
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. (2018) (32)
Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia (2008) (32)
Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study (2015) (32)
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia (2000) (32)
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia (2016) (32)
Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia. (2014) (32)
Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. (1996) (32)
Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints. (2000) (32)
Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. (2020) (31)
Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. (1997) (31)
Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML (2017) (31)
JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients (2009) (31)
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group fo (1995) (31)
PKR activity is required for acute leukemic cell maintenance and growth: A role for PKR‐mediated phosphatase activity to regulate GSK‐3 phosphorylation (2009) (31)
Host origin of bone marrow fibroblasts following allogeneic bone marrow transplantation for chronic myeloid leukemia. (1992) (31)
Fanconi anemia gene variants in therapy-related myeloid neoplasms (2015) (31)
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. (2006) (30)
Complete paraplegia after Nelarabine treatment in a T‐cell acute lymphoblastic leukemia adult patient (2010) (30)
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation (1999) (30)
Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination (2010) (30)
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis (2011) (30)
CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults (2020) (30)
Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy (2019) (30)
Transfusion History, T Cell Subsets and Natural Killer Cytotoxicity in Patients with Colorectal Cancer 1 (1989) (30)
Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. (2004) (29)
Efficacy of Dasatinib in Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from START-L (CA180-015). (2007) (29)
Supplementary Data 1 (2013) (29)
Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase. (2004) (29)
Colorectal carcinoma associated with ulcerative colitis: a study of prognostic indicators. (1992) (29)
Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation (2009) (29)
Immediate Breast Reconstruction and High-Dose Chemotherapy (2005) (29)
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments (2021) (29)
Signet ring cell lymphoma: a case report (1981) (29)
The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia (2017) (29)
Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia (2000) (29)
Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types. (2007) (29)
Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results. (1993) (29)
A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study. (2005) (29)
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’ (2010) (28)
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation (2006) (28)
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia (2018) (28)
Supplementary Data 2 (2013) (28)
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation (2006) (28)
Phase III trial with and without lonidamine in non-small cell lung cancer. (1991) (28)
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. (2014) (28)
Relationship between genome and epigenome - challenges and requirements for future research (2014) (28)
PKR is activated in MDS patients and its subcellular localization depends on disease severity (2008) (28)
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. (2010) (28)
Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR–ABL1-positive acute lymphoblastic leukemia patients (2010) (27)
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. (2021) (27)
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) (2011) (27)
Nilotinib ( formerly AMN 107 ) , a highly selective BCR-ABL tyrosine kinase inhibitor , is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia (2008) (27)
P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia (2016) (27)
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC. (2003) (27)
Procalcitonin as a useful marker of infection in hemato-oncological patients with fever. (2008) (27)
Selection and transplantation of autologous CD34+ B‐lineage negative cells in advanced‐phase multiple myeloma patients: a pilot study (1999) (27)
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. (2019) (27)
Combined-modality treatment of small-cell lung cancer: Randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest (1994) (27)
In vitro amplification of hypervariable DNA regions for the evaluation of chimerism after allogeneic BMT. (1993) (27)
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients (2016) (27)
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia (2020) (27)
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC. (2003) (27)
The molecular anatomy of the FIP1L1-PDGFRA fusion gene (2009) (27)
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia (2015) (26)
Supplementary Figure S6 (2012) (26)
Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib (2007) (26)
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. (2006) (26)
Molecular analysis of PML‐RARa fusion mRNA detected by reverse transcription‐polymerase chain reaction assay in long‐term disease‐free acute promyelocytic leukaemia patients (1995) (26)
Old and new prognostic factors in acute myeloid leukemia with deranged core‐binding factor beta (2013) (26)
Supplementary Data 3 (2013) (26)
A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results (2011) (26)
RAD 001 (everolimus) prevents mTOR and Akt late re‐activation in response to imatinib in chronic myeloid leukemia (2009) (26)
A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line (2017) (26)
The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias (2015) (26)
All‐trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia (2000) (26)
Early detection of bone marrow engraftment by amplification of hypervariable DNA regions. (1997) (26)
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants (2016) (26)
Dasatinib as Front-Line Monotherapy for the Induction Treatment of Adult and Elderly Ph+ Acute Lymphoblastic Leukemia (ALL) Patients: Interim Analysis of the GIMEMA Prospective Study LAL1205. (2007) (25)
Flai (fludarabine, cytarabine, idarubicin) plus low‐dose Gemtuzumab Ozogamicin as induction therapy in CD33‐positive AML: Final results and long term outcome of a phase II multicenter clinical trial (2018) (25)
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance (2013) (25)
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial (2022) (25)
The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis. (2015) (25)
Main changes in European Clinical Trials Regulation (No 536/2014) (2018) (25)
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment (2015) (25)
Cryptic translocation of PML/RARA on 17q. A rare event in acute promyelocytic leukemia. (2002) (25)
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. (2007) (24)
Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells. (1999) (24)
The cytogenetic response as a surrogate marker of survival. (2003) (24)
Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. (2002) (24)
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) (2015) (24)
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia (2007) (24)
Molecular therapy for multiple myeloma. (2001) (24)
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia (2021) (24)
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia (2007) (24)
Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. (1996) (24)
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin (2012) (23)
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes (2019) (23)
Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation (2004) (23)
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. (2008) (23)
Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation (2004) (23)
Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells. (1994) (23)
Imatinib mesylate in the treatment of hematologic malignancies (2007) (23)
Adrenal hemangiomas: two case reports with a review of the literature. (1989) (23)
Imatinib mesylate in the treatment of hematologic malignancies (2007) (23)
Extraperitoneal radical cystectomy and ureterocutaneostomy in octogenarians (2011) (23)
Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy (2009) (23)
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long‐term results and prognostic factors (2011) (23)
Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323 (2014) (23)
Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. (2013) (23)
Primary malignant fibrous histiocytoma of the spleen: an ultrastructural study (1982) (23)
Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine (2013) (22)
BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle. (1997) (22)
Early versus late alternating chemotherapy in small-cell lung cancer (1995) (22)
Abstract CT184: Gilteritinib significantly prolongs overall survival in patients withFLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial (2019) (22)
Granulocytic sarcomas: clinical, diagnostic and therapeutical aspects. (1997) (22)
Changes in peripheral T-cell subsets and natural-killer cytotoxicity in relation to colorectal cancer surgery. (1986) (22)
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate (2008) (22)
High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party (2008) (22)
Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia (2012) (22)
Significance of DNA content abnormalities in small rectal cancers. (1990) (22)
Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods (1998) (22)
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? (2019) (22)
Recommendations of the European Working Group for Adult ALL (2011) (22)
Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). (1999) (22)
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients (2020) (22)
Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer (2019) (21)
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis (2017) (21)
PI-PLCβ-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes (2008) (21)
Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients (2018) (21)
Case–control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients (2007) (21)
New targets for Ph+ leukaemia therapy. (2009) (21)
Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10 (2014) (21)
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients (2015) (21)
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis (2017) (21)
IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia (2015) (21)
CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study (2008) (21)
Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. (2009) (21)
PET/CT in Multiple Myeloma: Beyond FDG (2021) (20)
Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study (2010) (20)
Supplementary Data 4 (2012) (20)
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia (2021) (20)
The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone. (2014) (20)
Plerixafor and Filgrastim XM02 (Tevagastrim®) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation (2012) (20)
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia. (2011) (20)
Four‐chromosomes complex translocations in acute promyelocytic leukemia: Description of two cases (1994) (20)
Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial (2010) (20)
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol (2021) (20)
The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window? (2019) (20)
The type of BCR/ABL junction does not predict the survival of patients with Ph1‐positive chronic myeloid leukaemia (1993) (20)
NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms (2015) (19)
The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories (2012) (19)
Primary role of multiparametric flow cytometry in the diagnostic work‐up of indolent clonal mast cell disorders (2011) (19)
A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. (2007) (19)
Neutralizing anti‐interferon‐α antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (α2a) and lymphoblastoid interferon‐α (1996) (19)
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. (2009) (19)
Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. (2008) (19)
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer (2007) (19)
Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer (2020) (19)
Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma (2007) (19)
Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat (2004) (19)
The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. (2015) (18)
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy (2017) (18)
Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). (2019) (18)
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients (2016) (18)
Absence of bi‐directional cross‐resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms (2013) (18)
Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki‐67 labeling index (2004) (18)
Differences among young adults, adults and elderly chronic myeloid leukemia patients. (2015) (18)
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study (2016) (18)
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆. (2020) (18)
Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia (2002) (18)
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML (2019) (18)
Rituximab in Lymphocyte-Predominant Hodgkin Disease (2008) (18)
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program (2020) (18)
Bone marrow transplantation monitoring by DNA analysis. (1989) (18)
Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. (1997) (18)
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. (2014) (18)
Interleukin‐11 (IL‐11) acts as a synergistic factor for the proliferation of human myeloid leukaemic cells (1995) (18)
ALL‐TRANS RETINOIC ACID IMPROVES ERYTHROPOIESIS IN MYELODYSPLASTIC SYNDROMES: A CASE REPORT (1992) (17)
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia (2018) (17)
Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. (2004) (17)
Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i). (2006) (17)
An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL) (2014) (17)
Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2008) (17)
Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy (2000) (17)
Real‐world experience with decitabine as a first‐line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy (2019) (17)
Prognostic significance of DNA content abnormalities in young patients with colorectal cancer. (1989) (17)
High‐dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors (2013) (17)
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. (2019) (17)
Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line (2008) (17)
Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease. (2012) (17)
Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. (2004) (17)
Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis (2010) (17)
Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia. (2018) (17)
Phase I study of the combination of monthly carboplatin and weekly cisplatin. (1991) (17)
Efficacy of 90Yttrium‐ibritumomab tiuxetan in relapsed/refractory extranodal marginal‐zone lymphoma (2014) (17)
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis (2007) (17)
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine (2006) (17)
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. (2013) (17)
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase. (2003) (16)
First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (2014) (16)
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition (2019) (16)
Germline polymorphisms and survival of lung adenocarcinoma patients: A genome‐wide study in two European patient series (2015) (16)
Clinical and biological data on the use of hydroxychloroquine against SARS‐CoV‐2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease (2020) (16)
Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19 (2021) (16)
Novel Agents for Acute Myeloid Leukemia (2018) (16)
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells. (2013) (16)
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study. (2007) (16)
The use of pronase enhances sensitivity of the PAP method in the detection of intracytoplasmic immunoglobulins. (1980) (16)
Molecular analysis of granulocytic sarcoma: a single center experience. (1999) (16)
Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. (2000) (16)
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study. (2007) (16)
Nuclear factor-erythroid 2 (NF-E2) expression in normal and malignant megakaryocytopoiesis (2002) (16)
Clinical manifestation of severe hyperammonaemia in patients with multiple myeloma. (1997) (16)
Extramedullary myeloid sarcoma of the breast. (2008) (16)
Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia (2019) (16)
Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature. (2003) (15)
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies (2022) (15)
DNA hypermethylation promotes the low expression of pro‐apoptotic BCL2L11 associated with BCR‐ABL1 fusion gene of chronic myeloid leukaemia (2012) (15)
Fludarabine Combination Regimen Severely Affected Peripheral Blood Stem Cell Mobilization (2004) (15)
Enasidenib and Ivosidenib in AML. (2020) (15)
Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy (2009) (15)
Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia (2017) (15)
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib. (2014) (15)
Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin's disease in complete hematological remission. (1998) (15)
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study (2017) (15)
Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. (2004) (15)
Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment (2014) (15)
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia (2009) (15)
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2020) (15)
Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature. (2003) (15)
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy (2021) (14)
Molecular analysis of six variant Philadelphia chromosome translocations in chronic myeloid leukemia. (1993) (14)
Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study (2018) (14)
High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study. (2005) (14)
Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia (2019) (14)
Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. (2003) (14)
Chlorambucil–rituximab as first‐line therapy in patients affected by follicular non‐Hodgkin's lymphoma: a retrospective single‐centre study (2015) (14)
Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035 (2008) (14)
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients (2016) (14)
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge (2008) (14)
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. (2014) (14)
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors (2020) (14)
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia (2017) (14)
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience. (2011) (14)
BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia (2013) (14)
The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells (2016) (14)
Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. (1995) (14)
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma (2020) (14)
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study (2005) (14)
Juvenile papillomatosis of the breast. A multidisciplinary study. (1991) (14)
Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis (2013) (14)
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution. (2009) (14)
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia (2005) (14)
Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer (2004) (14)
Advances in the treatment for haematological malignancies (2006) (13)
Concamitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient (1999) (13)
Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML) (2019) (13)
Magnetic resonance imaging of primary breast lymphoma (2009) (13)
t(8;14)(q11;q32) in acute lymphoid leukemia: description of two cases. (1993) (13)
ChlVPP/ABVVP, a first line ‘hybrid’ combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis (2004) (13)
Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial (2014) (13)
Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia (2002) (13)
Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies (2010) (13)
Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission. (2004) (13)
Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. (2010) (13)
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial (2022) (13)
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies (2011) (13)
ras and c-myc protein expression in colorectal carcinoma (1992) (13)
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study (2017) (13)
Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission. (2004) (13)
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia (2013) (13)
Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14). (2006) (13)
Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia (2002) (13)
Chromosome instability and translocation t(11;18) in primary gastric marginal zone B‐cell lymphoma of MALT‐type (2007) (13)
[Giant cell arteritis of the uterus]. (1981) (13)
Clinical Outcomes in Patients With FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplant After Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. (2020) (12)
New generation anaplastic lymphoma kinase inhibitors. (2019) (12)
Novel FLT3 point mutation in acute myeloid leukaemia. (2003) (12)
Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. (2007) (12)
Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow (1998) (12)
Interleukin-9 in human myeloid leukemia cells. (1997) (12)
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia (2018) (12)
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors (2019) (12)
Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy. (1998) (12)
Stroma cells: a novel target of herceptin activity. (2003) (12)
Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. (1998) (12)
Lymphocyte subsets, natural killer cytotoxicity, and perioperative blood transfusion for elective colorectal cancer surgery. (1987) (12)
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients (2020) (12)
Myeloid sarcoma of liver: an unusual cause of jaundice. Report of three cases and review of literature (2007) (12)
Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial) (2011) (12)
Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study, (2011) (12)
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia (2015) (12)
A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma. (2010) (12)
Sclerosing stromal tumor of the ovary. A hormonal, histochemical and ultrastructural study. (1983) (12)
CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies (2022) (12)
Chronic myeloid leukemia, BCR/ABL transcript, response to alpha-interferon and survival. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. (1995) (12)
Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia (2019) (12)
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. (1999) (12)
Case of bilateral ovarian metastasis from regressed melanoma. (1984) (11)
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one. (2002) (11)
Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia (2013) (11)
M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia. (1992) (11)
Efficacy of Vinblastine, Bleomycin, Methotrexate (VBM) Combination Chemotherapy with Involved Field Radiotherapy in Early Stage (I-IIA) Hodgkin Disease Patients (2003) (11)
Present and future of molecular monitoring in chronic myeloid leukaemia (2016) (11)
Safety of FLT3 inhibitors in patients with acute myeloid leukemia (2021) (11)
New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia (2009) (11)
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era (2014) (11)
Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist (2011) (11)
Comparison of JAK2V617F‐positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology (2018) (11)
The BCR-ABLT 315 I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors , in a matched pair analysis (2013) (11)
The Benefit of Treatment with Quizartinib and Subsequent Bridging to HSCT for FLT3-ITD(+) Patients with AML (2014) (11)
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. (2004) (11)
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia (2006) (11)
TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors (2020) (11)
Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients (2010) (11)
Rotation of nilotinib and imatinib for first‐line treatment of chronic phase chronic myeloid leukemia (2016) (11)
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage (2017) (11)
Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells (2020) (11)
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma (2021) (11)
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia (2006) (11)
Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors (2019) (11)
Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study (2010) (11)
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance (2007) (11)
BCR–ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy (2011) (11)
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. (2004) (11)
Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study (2014) (11)
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia (2012) (11)
Angioimmunoblastic T‐cell lymphoma with hyperplastic germinal centres and a high content of EBV‐infected large B‐cells carrying IgH chain gene monoclonal rearrangement (2005) (10)
FLT3 inhibition as tailored therapy for acute myeloid leukemia. (2003) (10)
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop (2013) (10)
An atypical (b3/a3) junction of the bcr/abl gene lacking abl exon a2 in a patient with chronic myeloid leukemia. (1999) (10)
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model (2020) (10)
Chronic Myeloid Leukemia (CML) Patients with “Suboptimal” Response to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to “Optimal” Responders: A GIMEMA CML WORKING PARTY Analysis. (2009) (10)
Association of 3 q 21 q 26 syndrome with different RPN 1 / EVI 1 fusion transcripts (2003) (10)
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial. (2009) (10)
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? (2005) (10)
Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia. (2009) (10)
The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party. (2009) (10)
An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. (2017) (10)
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations (2021) (10)
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia (2021) (10)
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia (2021) (10)
Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia (2015) (10)
Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). (2018) (10)
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? (2005) (10)
Hydroxychloroquine as Prophylaxis for COVID-19: A Review (2020) (10)
Bone marrow necrosis by diffuse metastatic intravascular obstruction. (1982) (10)
New strategies for selection of unrelated bone marrow donors. (1993) (10)
Association of 3 q 21 q 26 syndrome with different RPN 1 / EVI 1 fusion transcripts (2003) (10)
Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. (2017) (10)
Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL). (2010) (10)
Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells. (1994) (10)
Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT Type) (2002) (10)
Core needle biopsy as a front line diagnostic approach for lymphoma patients (2015) (10)
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups (2013) (10)
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial. (2009) (10)
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. (2012) (10)
Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer (2021) (10)
Who should be really considered as a poor mobilizer in the plerixafor era? (2012) (10)
FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives. (2020) (10)
Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib (2016) (10)
The HLA class I-CML association revisited taking into account the two forms of gene fusion in the Philadelphia chromosome. A multicenter study. (1994) (9)
ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma (2003) (9)
Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio. (2019) (9)
Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2) (1999) (9)
Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients. (1993) (9)
Randomized phase III study of high-dose sequential chemotherapy (CT) supported by peripheral blood progenitor cells (PBPC) for the treatment of small cell lung cancer (SCLC): Results of the EBMT Random-ICE trial. (2006) (9)
BCR breakpoint subregions and blast crisis lineage in CML patients. (1992) (9)
Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts). (2006) (9)
Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript. (2000) (9)
Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients (2020) (9)
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab‐ozogamicin in adult refractory B‐acute lymphoblastic leukemia (2009) (9)
Protein Tyrosine Phosphatase Receptor Type γ Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia (2010) (9)
Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors. (2007) (9)
Long-term molecular complete remission with IFN-α in Ph+ adult acute lymphoid leukemia patients (2008) (9)
Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers (2018) (9)
Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia. (2013) (9)
Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. (2009) (9)
Interleukin‐4 Downregulates Nuclear Factor‐Erythroid 2 (NF‐E2) Expression in Primary Megakaryocytes and in Megakaryoblastic Cell Lines (2001) (9)
UPDATED SAFETY AND EFFICACY RESULTS OF PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN TREATMENT-NAIVE ACUTE MYELOID LEUKEMIA PATIENTS AGED >= 65 YEARS AND UNFIT FOR STANDARD INDUCTION THERAPY (2017) (9)
Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors. (2007) (9)
Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation. (1996) (9)
Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure. (2006) (9)
Phase 1 / 2 study to assess the safety , efficacy , and pharmacokinetics of barasertib ( AZD 1152 ) in patients with advanced acute myeloid leukemia (2011) (9)
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia (2019) (9)
Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML). (2013) (9)
Primary cardiac non‐Hodgkin lymphoma presenting with atrial flutter and pericardial effusion (2006) (9)
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138−CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis (2016) (9)
Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures (1999) (9)
Analysis of Glucose Profiles in Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia (CML) Patients (pts) Treated with Nilotinib: Lack of Correlation between Glucose Levels and Nilotinib Efficacy. (2007) (9)
DNA Methyltransferase 1 Drives Transcriptional Down‐Modulation of β Catenin Antagonist Chibby1 Associated With the BCR‐ABL1 Gene of Chronic Myeloid Leukemia (2015) (9)
Detection of clonality by heteroduplex analysis of amplified junctional region of T-cell receptor gamma in patients with T-cell acute lymphoblastic leukemias. (1997) (9)
Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML / RAR a Fusion Gene in Patients With Acute Promyelocytic Leukemia (1998) (9)
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia (2003) (9)
Suppression of Bcr-Abl Expression in CML by A Panel of miRNAs. (2009) (9)
Long-term molecular complete remission with IFN-α in Ph+ adult acute lymphoid leukemia patients (2008) (9)
Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts). (2006) (9)
A rare case of Hemoglobin Leiden interfering with the DIFF channel of Sysmex XE-2100 (2015) (9)
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results (2009) (9)
Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio. (2007) (9)
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin (2019) (9)
Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL) (2005) (9)
Adrenomedullin in the growth modulation and differentiation of acute myeloid leukemia cells. (2016) (9)
cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib (2006) (8)
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia (2005) (8)
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation (2013) (8)
Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease (2021) (8)
Patient with ataxia telangiectasia who developed acute myeloid leukemia (2011) (8)
Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance. (2007) (8)
Chronic myeloid leukemia: the basis of treatment for tomorrow (2011) (8)
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens (2021) (8)
A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS. (2017) (8)
Management of anaplastic large-cell lymphoma during pregnancy. (2009) (8)
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups (2013) (8)
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia. (1996) (8)
The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. (2018) (8)
ABL Mutations in Late-Chronic Phase Chronic Myeloid Leukemia Patients with Cytogenetic Refractoriness to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival. on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia. (2004) (8)
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib (2022) (8)
Hypereosinophilic syndrome and molecularly targeted therapy (2007) (8)
Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. (2010) (8)
Sexuality in patients undergoing haematopoietic stem cell transplantation (2011) (8)
High Dose 90Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study. (2006) (8)
A Prospective Study in Ph+ Chronic Myeloid Leukemia (CML) Patients Showing That Interphase Fluorescence in Situ Hybridization (FISH) Is Effective as Conventional Cytogenetics for Definition of Cytogenetic Response. Correlation with Molecular Response (by the GIMEMA CML WP). (2006) (8)
Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts. (2005) (8)
Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure (2007) (8)
Babesia infection in Italy. (2004) (8)
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia (2005) (8)
DNA Methylation in Chronic Myeloid Leukemia (2016) (8)
A Novel 4-anilino-3-quinolinecarbonitrile dual Src And Abl Kinase Inhibitor (SKI-606) Has In Vitro Activity On CML Ph+Blast Cells Resistant To Imatinib (2004) (8)
The p210BCR-ABL tyrosine kinase of chronic myeloid leukemia causes resistance to radio-induced apoptotic death by inhibiting the proapoptotic BAX gene (2004) (8)
Role of autologous bone marrow transplantation as consolidation therapy in acute promyelocytic leukemia patients in complete remission. (1998) (8)
Hypereosinophilic syndrome and molecularly targeted therapy (2007) (8)
Donor origin of hematopoiesis after a case of allogeneic transplantation with cryopreserved marrow. (1993) (8)
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03 (2009) (8)
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients (2011) (8)
Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies. (2016) (8)
Cisplatin, Etoposide and Continuous Infusion Bleomycin in Patients with Testicular Germ Cell Tumors: Efficacy and Toxicity Data from a Retrospective Study (2009) (8)
The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation (2015) (8)
The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study. (1991) (8)
What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity? (2014) (8)
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement. (2020) (8)
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. (2011) (8)
Peripheral T-lymphocyte subsets in patients treated with Rituximab–Chlorambucil combination therapy for indolent NHL (2006) (8)
A randomized study of interferon- a versus interferon- a and low-dose arabinosyl cytosine in chronic myeloid leukemia (2002) (8)
Long‐term molecular remission with persistence of BCR‐ABL1‐specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia‐positive ALL (2014) (8)
Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: Results of a phase II trial of the GIMEMA CML WP. (2009) (8)
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients (2001) (8)
The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients (2018) (8)
Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma. (1999) (7)
Response to Dasatinib in Patients with Aggressive Systemic Mastocytosis with D816V Kit Mutation. (2007) (7)
Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML. (2005) (7)
Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission. (2004) (7)
Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist (2016) (7)
Hematologic, cytogenetic and molecular response to Glivec (STI571) in Ph+ chronic myeloid leukemia (CML) in accelerated and blastic phase: a prospective study of the Italian cooperative study group on CML (2001) (7)
q 21 and 3 q 26 cytogenetic abnormalities in acute myeloblastic leukemia : biological and clinical features (1999) (7)
A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib. (2005) (7)
A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. (2020) (7)
Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib (2020) (7)
New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells (2010) (7)
bcr/abl chimeric transcript in patients in remission after marrow transplantation for chronic myeloid leukemia: higher frequency of detection and slower clearance in patients grafted in advanced disease as compared to patients grafted in chronic phase. (1995) (7)
Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant Program (2003) (7)
A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia. (2016) (7)
Chemotherapy-based regimens in multiple myeloma in 2020. (2020) (7)
Response to Dasatinib in Patients with Aggressive Systemic Mastocytosis with D816V Kit Mutation. (2007) (7)
Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). (2009) (7)
Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura (2000) (7)
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor , A 443654 , in T-Acute Lymphoblastic Leukemia (2008) (7)
LAL0201-B protocol of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) acute lymphoblastic leukemia without additional chemotherapy: results survival in elderly Philadelphia chromosome-positive patients with Imatinib plus steroids induces complete remissions and prolonged (2009) (7)
Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307 (2012) (7)
Pha-739358: a pan-aurora kinase inhibitor (2009) (7)
Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study. (2006) (7)
Assessment of chimerism in sex-mismatched allogeneic bone marrrow transplants (allo-BMT) by in situ hybridization and cytogenetics. Is host cell percentage predictive of relapse? (1997) (7)
Myeloid metaplasia of the breast. A lesion which clinically mimics carcinoma. (1983) (7)
A prospective study of α-interferon and autologous bone marrow transplantation in chronic myeloid leukemia (1999) (7)
Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. (2009) (7)
Immunoglobulins (Ig) in circulating immune complexes (CIC) in cancer and inflammatory bowel disease (IBD). (1986) (7)
BCR/ABL rearrangement and leukemia phenotype (1999) (7)
Molecular Heterogeneity of the FIP1L1-PDGFRA Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases. (2004) (7)
MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia. (2019) (7)
Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely (2003) (7)
Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant. (2013) (7)
Benign myxoid hepatocellular tumor: a variant of liver cell adenoma. (2008) (7)
Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells (2017) (7)
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial (2020) (6)
Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations. (2009) (6)
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement: clinical implications. (2008) (6)
Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib. (2004) (6)
Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with inv(16). A retrospective study (2007) (6)
Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start? (2021) (6)
Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients. (2007) (6)
Lineage‐specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture (2020) (6)
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients (2011) (6)
Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells (2008) (6)
Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells (2020) (6)
Will molecular biology contribute to refine prognosis and to select treatment? The Molecular Biology Committee. Italian Cooperative Study Group on Chronic Myeloid Leukemia. (1993) (6)
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly. (2003) (6)
Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK). (1994) (6)
A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients. (2007) (6)
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin (2000) (6)
Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2021) (6)
Stability of Conversion Factors for BCR-ABL Monitoring - Implications for the Frequency of Validation Rounds (2010) (6)
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients (2018) (6)
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly. (2003) (6)
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia (2022) (6)
atreatment of high-risk , Philadelphia-positive chronic myeloid leukemia : Comparison of imatinib 400 mg and 800 mg daily in (2009) (6)
Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant) (2015) (6)
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and feature. (2020) (6)
[Pericardial effusion in patients with malignant neoplasms]. (1992) (6)
Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer. (2004) (6)
Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score (2008) (6)
Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literature. (2013) (6)
Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up. (2020) (6)
Primary cardiac lymphoma with isolated parenchymal central nervous system relapse: report of two cases and review of the literature (2014) (6)
Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy (2017) (6)
Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib. (2004) (6)
Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease. (2003) (6)
An assessment of chimeric transcript detection in CML patients after bone marrow transplantation. (1991) (6)
Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art (2020) (6)
Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis (2021) (6)
Purine analogs (fludarabine and 2-chlorodeoxyadenosine) as apoptosis-inducing drugs in CML therapy. (1996) (6)
Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib? (2009) (6)
Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant) (2015) (6)
Molecular analysis of HLA genes for the selection of unrelated bone marrow donor. (1995) (6)
Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera (2006) (6)
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS (2020) (6)
A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib. (2004) (6)
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q‐ deletion (2010) (6)
Prior treatment with a-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia (1998) (6)
Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy. (2016) (6)
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience (2021) (6)
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis (2016) (5)
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories (2017) (5)
Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial. (2016) (5)
Blinatumomab in Ph+ B-ALL: present and perspectives (2017) (5)
Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer. (1997) (5)
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications (2012) (5)
Interferon‐alpha may restore sensitivity to tyrosine‐kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation (2009) (5)
Two more inv(16) acute myeloid leukemia cases with infrequent CBFbeta-MYH11 fusion transcript: clinical and molecular findings. (2002) (5)
Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial (2019) (5)
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma (2022) (5)
Role of Hyperbaric Oxygenation Plus Hypofractionated Stereotactic Radiotherapy in Recurrent High-Grade Glioma (2021) (5)
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment (2008) (5)
Does the type of BCR/ABL junction predict the survival of patients with Ph1-positive chronic myeloid leukemia? (1995) (5)
The use of anthracycline at first‐line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi (2015) (5)
Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope. (2020) (5)
Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial. (2005) (5)
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML (2016) (5)
Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. (2009) (5)
How I manage frontline transplant-ineligible multiple myeloma (2020) (5)
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome (2014) (5)
[Endodermal sinus tumor. With presentation of the first case observed at the level of the rhinopharynx]. (1979) (5)
CPX-351 - Daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. (2020) (5)
The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases. (2001) (5)
C-erb-2 gene amplification and chromosomal anomalies in bladder cancer: preliminary results. (2005) (5)
Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders? (2005) (5)
Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis (2020) (5)
Interim 18 f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma (2008) (5)
Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia (2017) (5)
Short- and long-term safety of the 2 x 10(6) CD34+ cells/kg threshold for hematopoietic reconstitution after high-dose chemotherapy and peripheral blood progenitor cell support. (2002) (5)
Apoptosis induction with purine analogs on freshly isolated chronic myeloid leukemia cells. (1995) (5)
ORIGINAL ARTICLE The NF-jB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance (2006) (5)
In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations. (2007) (5)
124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY (2015) (5)
The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial. (2008) (5)
Chromothripsis in Acute Myeloid Leukemia: biological features and impact on survival (2017) (5)
Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient (2013) (5)
Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making (2019) (5)
The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. (2012) (5)
Local Thrombolytic Therapy in Cancer Patients with Central Venous Catheter Occlusion in Urgent Need of Antiblastic Treatment: A Single Institution Experience (2003) (5)
The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis (2012) (5)
Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome (2013) (5)
Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression (2010) (5)
Practical Considerations in the Treatment of Hepatocellular Carcinoma (1998) (5)
Current strategies for detection and approach to easurable residual disease in Acute Myeloid Leukemia. (2020) (5)
Clinical research activities during COVID-19: the point of view of a promoter of academic clinical trials (2021) (5)
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment (2008) (5)
Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial. (2005) (5)
ABVD vs BEACOPP escalated in advanced‐stage Hodgkin’s lymphoma: Results from a multicenter European study (2020) (5)
Serendipitous detection of Hemoglobin G-Ferrara variant with Sysmex DIFF channel. (2016) (5)
FINGERPRINTING OF HLA CLASS I GENES FOR IMPROVED SELECTION OF UNRELATED BONE MARROW DONORS (1996) (5)
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial. (2018) (5)
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities (2016) (4)
Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline #7060 (2008) (4)
A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia (2020) (4)
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl‐positive acute lymphoid leukaemia (2004) (4)
High dose 90Yttrium ibritumomab tiuxetan with PBSC support in refractory-resistant NHL patients: Preliminary results of a phase I/II study. (2006) (4)
Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop (2011) (4)
FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months. (2006) (4)
The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis. (2010) (4)
Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study (2013) (4)
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl‐positive acute lymphoid leukaemia (2004) (4)
DASATINIB MONOTHERAPY AS 1ST LINE TREATMENT OF PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS: UPDATE OF THE GIMEMA LAL1205 STUDY (2008) (4)
Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party (2008) (4)
BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing? (2015) (4)
Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five Versus Seven Consecutive Days) In Patients with Hairy Cell Leukemia (HCL) In the ICGHCL2004 Protocol by the Italian Cooperative Group on Hcl (2010) (4)
Old and new generation proteasome inhibitors in multiple myeloma. (2020) (4)
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin (2021) (4)
A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies. (2014) (4)
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS (2016) (4)
Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences (2018) (4)
Persistence of non clonal hematopoietic progenitor cells in blastic phase chronic myelogenous leukemia (CML). Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of Bone Marrow Transplantation (EBMT). (1994) (4)
Amplification of third-complementary-determining-region (CDR-III) of heavy chain immunoglobulin gene (IgH) in one hundred adult acute leukemias. (1997) (4)
Resistance to Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Leukemias: Which Mutations Matter? (2007) (4)
Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom’s Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab. (2007) (4)
Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue (2021) (4)
Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient (2021) (4)
Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial (2020) (4)
AICDA expression in BCR/ABL1‐positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile (2011) (4)
Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. (2022) (4)
Gastric lymphoma: diagnosis and follow-up of chemotherapy-induced changes using real-time ultrasonography: a report of three cases. (1990) (4)
Original article Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma (2005) (4)
Erratum: Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups (Blood Cancer Journal (2013) 3 (e147) DOI:10.1038/bcj.2013.46) (2014) (4)
Imputation reliability on DNA biallelic markers for drug metabolism studies (2012) (4)
Concurrent chromothripsis events in a case of TP53 depleted acute myeloid leukemia with myelodysplasia-related changes. (2019) (4)
Primary non-Hodgkin’s lymphoma of the breast: First report of the multicentre retrospective study of the International Extranodal Lymphoma Study Group (IELSG-15) (2005) (4)
Mosaic tumour blood vessels and high-dose chemotherapy for breast cancer. (2001) (4)
Genome-wide analysis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients identified recurrent copy number variations in genes regulating the cell cycle and the B-cell differentiation. (2008) (4)
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma (2015) (4)
Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer (2021) (4)
[Carcinosarcoma of the bladder]. (1977) (4)
[Angioedema due to acquired complement-C1-inhibitor deficiency in a female patient with non-Hodgkin lymphoma and autoimmune hemolytic anemia]. (1991) (4)
Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha. (1996) (4)
Monoclonal antibodies in multiple myeloma. (2020) (4)
Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients (2015) (4)
Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients (2011) (4)
Long-term disease-free acute promyelocytic leukemia patients really can be cured at molecular level. (1998) (4)
Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL). (2007) (4)
Correction to: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences (Leukemia, (2018), 32, 10, (2152-2166), 10.1038/s41375-018-0033-0) (2018) (4)
Meeting report: antisense oligonucleotides. (1994) (4)
Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing (2018) (4)
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study (2010) (4)
Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party (2011) (4)
Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing (2018) (4)
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia (2021) (4)
Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias. (2010) (4)
Comparison of whole-body diffusion-weighted magnetic resonance and FDG-PET/CT in the assessment of Hodgkin’s lymphoma for staging and treatment response (2014) (4)
FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months. (2006) (4)
Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia (2022) (4)
Systemic Reactions After Hymenoptera Sting And Raised Serum Tryptase Strongly Suggest Clonal Mast Cells Disorders (2009) (4)
Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis. (2004) (4)
'Fingerprinting' of HLA-DQA by polymerase chain reaction and heteroduplex analysis. (1996) (4)
Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor (2017) (4)
Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis). (2006) (4)
ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients. (1999) (3)
LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY (2015) (3)
Next‐generation sequencing improves BCR‐ABL1 mutation detection in Philadelphia chromosome‐positive acute lymphoblastic leukaemia (2021) (3)
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration. (2010) (3)
PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients (2013) (3)
Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments (2022) (3)
RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination. (2009) (3)
Collection of Ph-negative progenitor cells from Ph+ CML patients in complete cytogenetic remission after long-term interferon-alpha therapy. (1999) (3)
HIF 1 Alpha: A Suitable Target for Multiple Myeloma (2011) (3)
Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia (2021) (3)
A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia (2019) (3)
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells (2011) (3)
Targeting CDK 6 and BCL 2 Exploits the " MYB Addiction " of Ph + Acute Lymphoblastic Leukemia (2018) (3)
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells (2014) (3)
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform (2016) (3)
New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. (2020) (3)
BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor (2011) (3)
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia (2008) (3)
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis (2022) (3)
The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma (2011) (3)
Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents (2021) (3)
Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling. (2008) (3)
MK-0457: a light at the end of the tunnel? (2007) (3)
Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia (2020) (3)
Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (2019) (3)
Nilotinib 800 mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: results of a phase II trial of the GIMEMA CML Working Party (2008) (3)
Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107) (2010) (3)
Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG (2011) (3)
BCMA-targeting approaches for treatment of multiple myeloma. (2020) (3)
BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia. (2009) (3)
5-Azacytidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial (2008) (3)
Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis (2015) (3)
Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series (2021) (3)
Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase. (1999) (3)
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters (2022) (3)
[Clinically primary malignant lymphoma of the skeletal muscle (presentation of a case and review of literature)]. (1979) (3)
Neurosecretory-like granules in non-Hodgkin's malignant lymphomas. (1984) (3)
Sequential high-dose chemotherapy (SHDC) with autologous stem cell transplantation (ASCT) vs standard CHOP regimen for pts with untreated aggressive NHL. Result of the mistral trial from the Swiss Group for Clinical Cancer Research (SAKK) (2005) (3)
Treatment free remission in chronic myeloid leukemia: Lights and shadows (2020) (3)
Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial. (2021) (3)
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon (2022) (3)
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway (2021) (3)
Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial (2019) (3)
Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis (2018) (3)
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients (2014) (3)
Therapy-related acute leukemia associated with involvement of 11q23 after high grade non-Hodgkin lymphoma. (1998) (3)
Efficacy and toxicity of FLAI vs ICE for induction treatment of newly diagnosed AML patients, younger than 60 years (2004) (3)
Neoadjuvant therapy with oxaliplatin (OXA) and 5-fluorouracil (5FU) continuous infusion (CI) combined with radiotherapy (RT)in rectal cancer: First results of the Bologna phase II study (2004) (3)
Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year. (2008) (3)
MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences. (2017) (3)
Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement. (2005) (3)
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a (2021) (3)
Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy. (2019) (3)
Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule. (2004) (3)
Abstract 5552: Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408 (2014) (3)
Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin? (2018) (3)
Alpha-Interferon Alone or in Combination with Chemotherapy in the Treatment of Malignant Melanoma, Renal Cell Carcinoma and other Solid Tumours (1987) (3)
In vivo endocrine studies and morphological features in a case of hilus cell tumor in mesovarium. (1982) (3)
A competency based educational programme for research nurses: an Italian experience (2009) (3)
Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes (2021) (3)
A Case Report of Acute Myeloid Leukemia and Neurofibromatosis 1 (2013) (3)
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis (2020) (3)
Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia (2021) (3)
Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia (2021) (3)
Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib. (2010) (3)
Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia (2020) (3)
Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation (2018) (3)
Release of IFN-γ by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. (2022) (3)
Allogeneic stem cell transplants for multiple myeloma. Bologna experience (1998) (3)
BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis. (2010) (3)
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). (2009) (3)
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia (2020) (3)
Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation (2020) (3)
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies (2012) (3)
First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy. (2006) (3)
EphA3 Kinase Is Constitutively Activated in Chronic Myeloid Leukaemia during Progression to Accelerated and Blast Crisis and It Could Represent a New Molecular Target. (2008) (3)
The New Italian Mastocytosis Registry. (2010) (3)
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). (2009) (3)
Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year. (2008) (3)
Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series (2021) (3)
Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia. (2021) (3)
New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. (2020) (3)
Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (2021) (3)
Achieving aMajor Molecular Response at theTime of a Complete Cytogenetic Response ( CCgR ) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients (2006) (3)
Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib. (2012) (3)
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a (2021) (3)
DNA ploidy of colorectal cancer and synchronous polyps in polyposis coli (1991) (3)
The molecular pathogenesis of multiple myeloma (2020) (3)
A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. (2003) (2)
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (2011) (2)
Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma). (2009) (2)
R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma. (2014) (2)
Secondary haematological malignancies after radioimmunotherapy (2012) (2)
Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients, (2011) (2)
Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL. (2019) (2)
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia (2021) (2)
Endostatin induces tumor stabilization after chemo- or ANTI-CD20 therapy of high-grade non-hodgkin's lymphoma (Nhl) (2000) (2)
European multicenter experience on idiopathic hypereosinophilic syndrome (HES) with FIP1L1-PDGFRA rearrangement treated with Imatinib (2004) (2)
What We Don't Know About Resistance to Tyrosine Kinase Inhibitors in CML: What Makes CML Cells a Tougher Enemy Than Expected? (2008) (2)
High grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma (2022) (2)
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia (2014) (2)
Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy (2013) (2)
Binding mode of the tyrosine kinase inhibitor bosutinib (SKI-606) to Abl kinase (2007) (2)
Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients (2019) (2)
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol (2021) (2)
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. (2020) (2)
Taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC): A promising drug combination (1997) (2)
Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters (2015) (2)
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia. (2017) (2)
Gross hematuria 10 years after radical cystectomy: adenomatous polyp. (2004) (2)
Valganciclovir Is Safe and Effective as Pre-Emptive Treatment for CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation. (2006) (2)
Prompt Resolution of Nasal Aspergillosis with Intra-Nasal Instillation of Liposomal Amphotericin-B (Ambisome®) and Granulocyte Transfusions (2004) (2)
Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean). (2004) (2)
Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I-B35 molecules: relationship between antigen defective cell lines and HLA frequencies in CML patients. (1995) (2)
Phase I/II Study of Tipifarnib and Bortezomib in the Treatment of Poor Risk Adult Acute Myeloid Leukemia (2008) (2)
Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients. (2005) (2)
Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow –up of 30 to 92 Months. (2009) (2)
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION (2009) (2)
Abstract 5279: Metabolic profiling defines a new characterization of acute myeloid leukemia and identifiesNPM1-mutated cases as a distinct subgroup (2019) (2)
The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway (2015) (2)
"ARMY": First-in-human study of the humanized, defucosylated monoclonal antibody (mAb) MEN1112/OBT357 targeting CD157 antigen, in relapsed or refractory (R/R) acute myeloid leukemia (AML). (2015) (2)
Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2021) (2)
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib. (2012) (2)
Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90 Y - Ibritumomab Tiuxetan. (2008) (2)
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome (2014) (2)
Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients. (2005) (2)
Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic (2009) (2)
High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients. (2007) (2)
Abstract 5491: Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience (2015) (2)
Prompt Resolution of Nasal Aspergillosis with Intra-Nasal Instillation of Liposomal Amphotericin-B (Ambisome®) and Granulocyte Transfusions (2004) (2)
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features (2016) (2)
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia (2021) (2)
Significance of detection of BCR/ABL transcript after allogeneic and autologous transplant. (1994) (2)
Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. (2020) (2)
Four Drugs Induction Therapy (fludarabine, cytarabine, idarubicin and gemtuzumab ozogamycin) for the Treatment of Elderly Acute Myeloid Leukemia Patients. (2009) (2)
Effect of combination of azacitidine and valproic acid on PI-PLCbeta1 signaling in high-risk myelodysplastic syndromes (2010) (2)
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis (2015) (2)
[Mechanism of splenic involvement in Hodgkin's lymphoma]. (1972) (2)
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia (2014) (2)
Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study (2016) (2)
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia (2019) (2)
Crucial Factors of the Inflammatory Microenvironment Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating Survival and Inhibiting Proliferation of CD34+ stem/Progenitor Cells (2014) (2)
Interferon-γ-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment (2019) (2)
Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML) (2019) (2)
[Lymphomatoid granulomatosis (report of a case and review of the literature)]. (1979) (2)
Control of Residual Disease in Imatinib Treated Chronic Myeloid Leukemia Patients with Peptide Vaccinations: 2 Years Follow up of CMLVAX100 Trial. (2005) (2)
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations (2016) (2)
Quantitative Evaluation of BCR-ABL Amount of Transcript Post Mobilization with G-CSF of Peripheral Blood Stem Cells from Chronic Myeloid Leukemia Patients in Cytogenetic Response (2000) (2)
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2022) (2)
Early molecular response to nilotinib in patients who failed imatinib is associated with a higher probability of cytogenetic response in chronic myeloid leukemia (CML) (2010) (2)
Different suppression of Ph1 positive hemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML. (1991) (2)
Imaging , Diagnosis , Prognosis CDKN 2 A / B Alterations Impair Prognosis in Adult BCR-ABL 1 – Positive Acute Lymphoblastic Leukemia Patients (2011) (2)
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. (2021) (2)
European multicenter experience on idiopathic hypereosinophilic syndrome (HES) with FIP1L1-PDGFRA rearrangement treated with Imatinib (2004) (2)
Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results (2019) (2)
Old and new generation immunomodulatory drugs in multiple myeloma. (2020) (2)
Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP. (2009) (2)
Baseline Biomarkers Influencing Clinical Outcomes in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Treated with Blinatumomab Versus Standard-of-Care Chemotherapy (SOC) from a Randomized Phase 3 Study (2017) (2)
Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis (2014) (2)
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients. (2010) (2)
Indolent lymphoma 295 ANALYSIS OF PROGNOSTIC FACTORS IN 424 MALT LYMPHOMA PATIENTS TREATED IN THE IELSG-19 MULTICENTER RANDOMISED STUDY (2011) (2)
Neoadjuvant therapy with oxaliplatin (OXA) and 5-fluorouracil (5FU) continuous infusion (CI) combined with radiotherapy (RT)in rectal cancer: First results of the Bologna phase II study. (2004) (2)
Abstract 906:Gas1andKif27genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients (2012) (2)
Genomic Analysis Of Notch Mutations In a Case Of Alagille Syndrome With Acute Lymphoblastic Leukemia (2013) (2)
Posterior Reversible Encephalopathy Syndrome in a B-Cell Acute Lymphoblastic Leukemia Young Adult Patient Treated with a Pediatric-Like Chemotherapeutic Schedule (2014) (2)
Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow –up of 30 to 92 Months. (2009) (2)
A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2021) (2)
Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation (2012) (2)
Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial (2019) (2)
995OInterim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS (2017) (2)
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia (2012) (2)
Efficacy and Tolerability of Liposomial Cytosine Arabinoside (DepoCyte®) for the Treatment of Lymphomatous and Leukemic Meningitis. (2006) (2)
Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party (2013) (2)
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis (2013) (2)
Imatinib Induced Re-Activation of FoxO3 Transcription Factor in CML Is Responsible for the Induction of a Quiescent Status of CD34 Leukaemic Progenitor Cells. (2008) (2)
Abstract 3889: Population pharmacokinetic/pharmacodynamic evaluation of the effect of glasdegib exposure on cardiac repolarization (QT interval) in cancer patients (2019) (2)
Prospective Exploratory Phase II Studies of A Rotating Regime of Nilotinib and Imatinib for Frontline Treatment of Philadelphia POSITIVE (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). (2009) (2)
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. (2021) (2)
Efficacy of 90 Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin’s Lymphoma. (2006) (2)
Gene Expression Profiling (GEP) of Myeloma (MM) Cells To Predict Attainment (near) Complete Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed MM. (2006) (2)
Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib (2013) (2)
Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK). (1995) (2)
Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories (2014) (2)
Communication skills and raising awareness in clinical practice: an Italian experience (2009) (2)
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk (2017) (2)
High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. (2009) (2)
Tissue Microarrays in Diffuse Large B-Cell Lymphomas (2011) (2)
IPO‐trimethylation of histone H3‐lysine9 associated with P210 BCR‐ABL tyrosine kinase of chronic myeloid leukaemia (2008) (2)
Disabled Gene Is Involved in CML Progression and Its Expression Level at Diagnosis Can Predict Major Molecular Response (MMR) to Imatinib Therapy. (2009) (2)
Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine. (2021) (2)
Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis (2007) (2)
Antibodies against human cytomegalovirus late protein UL 94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease (2012) (2)
The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate (2013) (2)
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy (2013) (2)
Nck Beta Adapter Protein Coordinates Bcr-Abl/Sam68 Intermolecular Interaction. (2008) (2)
The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling. (2007) (2)
Totally implantable central venous access ports connected to Groshong catheter for chemotherapy of solid tumours: Long-term results of 270 cases (1997) (2)
PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party. (2009) (2)
Quantitative Assessment of Indoleamine 2,3-Dioxygenase (IDO) Expression at Diagnosis Predicts Clinical Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation (2018) (2)
Low-dose imatinib therapy leads to rapid induction of major molecular responses with achievement of molecular remission in FIP1L1 -PDGFRA associated hypereosinophilic syndrome (2006) (2)
Equivalent Efficacy and Lower Toxicity of Subcutaneous Cladribine at Reduced Doses (Five versus Seven Consecutive days) in Hairy Cell Leukemia: An Interim Analysis of the ICGHCL 2004 Protocol by the Italian Cooperative Group on Hcl (2008) (2)
Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (2019) (2)
Tamoxifen protects breast cancer patients from COVID-19: first evidence from real world data (2021) (2)
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis (2015) (2)
No Preferential Sensitivity of t(8;21) Acute Myeloid Leukemias to Cytosine Arabinoside in Vitro: Is Intensity of Therapy or High Dose Ara-C Crucial for Response? (2004) (2)
Highly Sensitive Mutations Detection in BCR-ABL Positive Leukemia Prior and during Imatinib Treatment. (2004) (2)
Case Report: Analysis of Plasma Extracellular Vesicles in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient (2022) (1)
Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin’s lymphoma (2008) (1)
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment (2010) (1)
Supplementary Data Legends (2012) (1)
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma (2021) (1)
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors (2023) (1)
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis (2016) (1)
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. (2004) (1)
What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening (2017) (1)
Treatment for patients with indolent and mantle cell lymphoma (2013) (1)
Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma (2008) (1)
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial (2020) (1)
Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia (2015) (1)
Abstract 3811: A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) (2011) (1)
[Trabecular carcinoma of the skin]. (1983) (1)
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 (2016) (1)
Sensitive Detection of FIP1L1-PDGFRA Fusion Transcripts by Real-Time Quantitative RT-PCR (RQ-PCR) Reveals Achievement of Molecular Remission in Chronic Eosinophilic Leukemia Treated with Low-Dose Imatinib Therapy. (2005) (1)
[Blastoma of the lung--a rare malignancy. Case report]. (1993) (1)
Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML). (2006) (1)
Acute leukemias in 2020: state of the art. (2020) (1)
Aberrant Splicing of the SLP65 SH2 Domain Enables Pre-B Cell Transformation and Compromises the Leukemia-Suppressive Function of the Pre-B Cell Receptor (2008) (1)
Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) (2018) (1)
How we manage smoldering multiple myeloma (2020) (1)
Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party (2010) (1)
Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis (2008) (1)
Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling (2018) (1)
[Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine]. (1999) (1)
New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib (2009) (1)
CAR T cells targeting options in the fight against multiple myeloma. (2020) (1)
MM-499 Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone. (2019) (1)
The Oncogenic Kinase Bcr-Abl Directly Regulates Splicing of BclX through a Quaternary Complex Coordinated by Nck-Beta and Sam-68 Adapter Proteins. (2009) (1)
Abstract 311: Loss of the tumor suppressor genesCDKN2A/ARFimpairs prognosis in adultBCR-ABL1positive acute lymphoblastic leukemia (ALL) (2011) (1)
BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia (2008) (1)
Eosinophilic cellulitis: a new case (with 1 color plate). (1982) (1)
Response to Letter Regarding Article, “Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition” (2007) (1)
Abstract 746: PKC412 (Midostaurin) is safe and highly effective in systemic mastocytosis patients: Follow up of a single-center Italian compassionate use (2014) (1)
Abstract 656: High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) (2010) (1)
An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study (2021) (1)
FoxO Transcription Factor Is Delocalized and Inactivated in Acute Myeloid Leukaemia Patients. (2007) (1)
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). (2010) (1)
Epirubicin and docetaxel is a very effective regimen for peripheral blood progenitor cells (PBPC) mobilization (1998) (1)
One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806. (2010) (1)
Sensitive Detection of FIP1L1-PDGFRA Fusion Transcripts by Real-Time Quantitative RT-PCR (RQ-PCR) Reveals Achievement of Molecular Remission in Chronic Eosinophilic Leukemia Treated with Low-Dose Imatinib Therapy. (2005) (1)
Treatment With Quizartinib (AC220) Enables a High Rate of Patients With Relapsed or Refractory FLT3-ITD(+) Acute Myeloid Leukemia to be Bridged to HSCT (2014) (1)
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients (2014) (1)
The Interlaboratory RObustness of Next-Generation Sequencing (IRON) Study: Deep-Sequencing Investigating TET2 , CBL , and KRAS Mutations In 4464 Amplicons by An International Group Involving 8 Laboratories. (2010) (1)
A multicenter phase II study (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma (2011) (1)
Identification of Proteinase 3 (PR3) Gene Overexpresison and Protein Delocalization in Core Binding Factor Leukemias as a Mechanism Leading to Increased Chemosensitivity. (2008) (1)
ITALIAN STANDARDIZATION OF BCR-ABL RQ-PCR AND QUALITY CONTROL METHODS: AN OVERVIEW OF FIRST 4 YEARS RESULTS (2010) (1)
Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results (2008) (1)
Thyrosin kinase inhibitors: nilotinib (2009) (1)
High dose Y-90-Ibritumomab-Tiuxetan with autologous stem cell transplantation in refractory-resistant NHL patients (2010) (1)
The IKK Inhibitor PS1145 Allows to Overcome Imatinib Resistance. (2004) (1)
Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome (2019) (1)
Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL). (2005) (1)
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants (2016) (1)
[Leukemia and mycotic infections: report of a case of phycomycosis (author's transl)]. (1978) (1)
Midostaurin in acute myeloid leukemia: review of current evidence and practical considerations in routine clinical use. (2020) (1)
CLL 260 PROGNOSTIC VALUE OF ELEVATED POLYCLONAL SERUM FREE LIGHT CHAINS IN STAGE A CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS (2011) (1)
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) (2016) (1)
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. (2004) (1)
Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party. (2004) (1)
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients (2012) (1)
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients (2022) (1)
Case Report: A BRCA2 Mutation Identified Through Next-Generation Sequencing in a Birt–Hogg–Dubè Syndrome Family (2022) (1)
CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program (2021) (1)
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 , (2011) (1)
Stage I findings of a two-stage phase II study to assess the efficacy, safety, and tolerability of barasertib (AZD1152) compared with low-dose cytosine arabinoside (LDAC) in elderly patients (pts) with acute myeloid leukemia (AML). (2012) (1)
A rapid reduction of Bcr/Abl transcripts is associated with an early cytogenetic response to Glivec (STI571) in chronic myeloid leukemia in chronic phase: a study of the Italian cooperative study group on CML (2001) (1)
Abstract A27: European Network NGS-PTL preliminary data: Whole exome sequencing identifies mutations of ALDH2, RETSAT, HSPG2, CHPF and other metabolic genes as a novel functional category in acute myeloid leukemia (2016) (1)
Abstract #5611: Identification of new genes sustaining Bcr-Abl oncogenic signalling and CML progression through a genetic tool based on human Bcr-Abl transgenic Drosophila melanogaster (Dm) (2009) (1)
Pediatric Therapy In Adult Acute Lymphoblastic Leukemia: Updated Experience of a Single Centre (2010) (1)
MM-385: Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma (2020) (1)
THE ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST MINUTES OF INFECTION PREVENTION AND CONTROL COMMITTEE MEETING (2010) (1)
ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study (2019) (1)
Dose finding study of high-dose eplrubicln (E) and docetaxel (T) as first line chemotherapy in advanced breast cancer (ABC) (1997) (1)
PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use. (2014) (1)
PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG-120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (2019) (1)
May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML? (2007) (1)
Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia (2020) (1)
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. (2012) (1)
Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408. (2013) (1)
Cisplatin, etoposide and bleomycin infusion (PEBi regimen) in good-risk patients with germ cell tumors. (1997) (1)
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? (2020) (1)
Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis (2017) (1)
Atypical Chronic Myeloproliferative Disorders: Genes and Imatinib-Sensitive Targets (2007) (1)
Abstract 3100: Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experience (2016) (1)
Working Party on CML analysis adverse prognostic influence on frontline imatinib therapy: a GIMEMA Additional chromosomal abnormalities in Philadelphia-positive clone: (2013) (1)
ID-Ara-C, idarubicine and mylotarg gemtuzumab ozogamicin as salvage treatment in advanced AML patients (2007) (1)
Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMolR) at 12 Months (2010) (1)
Study on Sucrosomial® Iron Endocytosis-Mediated Uptake and Enterocytes Release (2018) (1)
Clinical significance of early molecular response in chronic myeloid leukemia patients treated frontline with imatinib mesylate. (2013) (1)
COMMONLY INACTIVATED BY DNA MUTATIONS AND DELETIONS IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (EMZL) (2008) (1)
Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients (2022) (1)
A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line (2016) (1)
Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib – A TOPS Correlative Substudy (2010) (1)
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment (2022) (1)
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination (2017) (1)
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (2021) (1)
Lonidamine (LND) vs mitomycin/vindesine (MV) vs MV + LND in extensive stage non-small-cell lung cancer (NSCLC) — A prospective randomized phase III-Trial (1991) (1)
[Case of universal calcinosis in dermatomyositis in childhood]. (1981) (1)
Growth Factor Production and Speed of Engraftment Correlate with Vascular Endothelial Frequency of Apoptotic Cells in Solid Tumors and Efficiency Diabetic / Severe Combined Immunodeficiency Mouse Model : Human Myeloid and Lymphoid Malignancies in the Non-Obese (2000) (1)
Effects of yoga practice on physiological distress, fatigue and QOL in patients affected by breast cancer undergoing adjuvant radiotherapy (2022) (1)
Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy. (2008) (1)
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report (2017) (1)
accelerated-phase chronic myelogenous leukemia inhibitor, is active in patients with imatinib-resistant or -intolerant Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase (2008) (1)
Whole Transcriptome Resequencing of Paired Diagnosis-Relapse BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Samples Reveals the Loss of Cell Cycle Regulation as the Main Mechanism Responsible for Leukemia Progression. (2010) (1)
Response to imatinib mesylate in patients with the FIP1L1-PDGFR-alpha positive hypereosinophilic syndrome: Update of a multicenter prospective study and guidelines for eosinophilia diagnosis (2008) (1)
Abstract 251: Disabled gene is involved in CML progression and its expression level at diagnosis can predict major molecular response (MMR) to imatinib therapy (2010) (1)
Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib (2012) (1)
Old age affects survival but not response in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML) patients treated with imatinib (IM): a study of the GIMEMA CML working party (2010) (1)
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. (2008) (1)
In vitro amplification of hypervariable DNA regions for the evaluation of chimerism after allogeneic bone marrow transplantation (1993) (1)
Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL (2013) (1)
The More Effective and the More (bio) Similar: Plerixafor and Filgrastim XM02 (tevagastrim) As First Line PBSC Mobilization Strategy in Patients with Multiple Myeloma and Lymphomas Candidate to ABMT (2011) (1)
IELSG Phase II Studies of Bortezomib in Malt Lymphomas. (2007) (1)
PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use. (2014) (1)
[Acute coronary occlusion of non bacterial thrombotic endocarditis (author's transl)]. (1977) (1)
Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity (2015) (1)
A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs (2016) (1)
Systematic Evaluation of Hypereosinophilic Syndrome-Related Organ Damage According to FIP1L1-PDGFRA Status and Response to the Therapy: Analysis from Prospective Clinical Trial with Imatinib Mesylate. (2007) (1)
Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT) (2010) (1)
Identification of Genes Sustaining Bcr-Abl Oncogenic Signalling and CML Progression through a Genetic Tool Based on Human Bcr-Abl Transgenic Drosophila Melanogaster. (2008) (1)
Abstract 2651: Deep hypoxia and the genomic background cooperate to shape the metabolic profile of acute myeloid leukemia cells (2019) (1)
Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph+ Acute Lymphoblastic Leukemia. (2009) (1)
Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study (2018) (1)
Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma (2010) (1)
Old Age Affects Survival but Not Response in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib (IM): A Study of the GIMEMA CML WORKING PARTY. (2009) (1)
Primary breast lymphoma (2008) (1)
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen (2010) (1)
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) (2011) (1)
Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment? (2020) (1)
FOUR-YEAR OUTCOME OF 215 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FRONTLINE: A GIMEMA CML WORKING PARTY ANALYSIS (2014) (1)
MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment (2018) (1)
Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party (2016) (1)
Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine (2020) (1)
High-Resolution Genome Wide Copy Number Alteration (CNA) and Loss of Heterozigosity (LOH) Analysis in Chronic Myeloid Leukemia (CML) Shows That High and Intermediate Sokal Risk Pts (Pts) Have Multiple Losses Targeting Genes Involved in DNA Repair. (2009) (1)
S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED (2019) (1)
Phase II trial of cladribine (2-CdA) and rituximab in patients with CLL and SLL: Preliminary report of a single institution (2007) (1)
MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment (2018) (1)
Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment. (2010) (1)
IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report. (2016) (1)
Abstract 656: High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) (2010) (1)
ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication. (2007) (1)
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience (2013) (1)
Abstract 2723: The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia (2016) (1)
Early lymphoid blastic crisis following major karyotypic conversion in a chronic myeloid leukemia patient treated with interferon-α (1994) (1)
Response to imatinib mesylate in patients with the FIP1L1-PDGFR-alpha positive hypereosinophilic syndrome: Update of a multicenter prospective study and guidelines for eosinophilia diagnosis (2008) (1)
Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial (2019) (1)
The Pre-B Cell Receptor Suppresses Leukemogenesis by Censoring MYC Expression. (2008) (1)
Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (2010) (1)
Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML (2014) (1)
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations (2009) (1)
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry (2008) (1)
Abstract 1229: Clonal hematopoiesis of indeterminate potential (CHIP), centenarians and age-related cardiovascular risk: Is TET2 the culprit (2018) (1)
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) (2012) (1)
An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease (2017) (1)
Systematic Evaluation of Hypereosinophilic Syndrome-Related Organ Damage According to FIP1L1-PDGFRA Status and Response to the Therapy: Analysis from Prospective Clinical Trial with Imatinib Mesylate. (2007) (1)
Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial. (2018) (1)
216 Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study (2011) (1)
Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era (2019) (1)
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia (2015) (1)
Case report Fournier's gangrene: a clinical presentation of necrotizing fasciitis after bone marrow transplantation (1998) (1)
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis. (2016) (1)
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis (2016) (1)
Expression Profiling of ABC Transporter Genes in Chronic Myeloid Leukemia (CML) and Responsiveness to Imatinib (2008) (1)
Genome-Wide Screening for Dominant Modifiers in Drosophila Identified New Cluster of Genes Involved in BCR-ABL Signalling and CML Progression. (2009) (1)
Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression. (2009) (1)
IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia (2015) (0)
Is there a role for ‘modified VAD’ in the treatment of multiple myeloma? (2009) (0)
PB2293 PEGFILGRASTIM VERSUS FILGRASTIM IN THE MANAGEMENT OF THERAPY-RELATED NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE (2019) (0)
In reply [2] (2005) (0)
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience. (2009) (0)
Advances in the biology and therapy of chronic myeloid leukemia (CML): Proceedings from the 6 th Post-ASH International CML and Myeloproliferative Neoplasms Workshop (2013) (0)
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. (2009) (0)
PS1346 CLONAL EVOLUTION IN MULTIPLE MYELOMA PATIENTS RECEIVING MAINTENANCE THERAPY (2019) (0)
Evolutionary Fitness of Relapsed Multiple Myeloma Patients Who Responded to Upfront Combination Therapy Including New Drugs (2017) (0)
FOXM 1 TRANSCRIPTION FACTOR : A NEW COMPONENT OF CHRONIC MYELOID LEUKEMIA STEM CELL PROLIFERATION ADVANTAGE † RUNNING HEAD : FOXM 1 in chronic myeloid leukemia (2017) (0)
Prognostic Value of BCL2 Determination in Follicular NHL Patients Treated with Alkylating Containing Regimen Alone or in Combination with Rituximab. (2004) (0)
Prognostic valude of Ki-67, TS, p53, bcl-2, EGFR, MLH1 and MSH2 in 107 consecutive colorectal cancer patients (2005) (0)
Short communication Cryptic translocation of PML/RARA on 17q. A rare event in acute promyelocytic leukemia (2002) (0)
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia. (2017) (0)
Interferon in CML: back to the past, or towards the future? (2015) (0)
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations (2017) (0)
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia (2011) (0)
Abstract 1758: A more mature immunophenotypic makeup of multiple myeloma clone(s) at diagnosis correlates with a higher genomic instability (2017) (0)
SIMILAR BUT NOT THE SAME: CHROMOSOMAL ABNORMALITIES T(8;21)(Q22;Q22) AND INV(16)(P13;Q22)/T(16;16)(P13;Q22) IDENTIFY SUBTYPES OF CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA CHARACTERIZED BY DIFFERENT SURVIVAL AND PROGNOS- TIC FACTORS (2013) (0)
Abstract P4-07-06: Breast cancer subtype classification using NanoString and RNAseq technologies (2020) (0)
P060 Effect of azacitidine on PI-PLC-beta1 expression and Akt activation in a patient affected by high-risk myelodysplastic syndrome (MDS) (2007) (0)
5-AZACITIDINE FIVE DAYS/MONTHLY SCHEDULE IN SYMPTOMATIC LOW-RISK (IPSS: 0-1) MYELODISPLASTIC (MDS) PATIENTS. CLINICAL AND BIOLOGICAL EFFECTSAuthors (2010) (0)
Lymphoma Surrogate Angiogenesis Marker in an Animal Model of Human Kinetics and Viability of Circulating Endothelial Cells As Updated (2001) (0)
Abstract 3189: The alternate activation of hedgehog pathway, either in CD138+ or in CD138-CD19+ multiple myeloma primary cells, impacts on disease outcome (2016) (0)
[Immunoperoxidase. Theoretical bases and possibilities of use in human pathology]. (1983) (0)
Continuous infusion endostatin abrogates high-grade lymphoma growth in vivo, possibly by inhibition of clonogenic endothelial progenitors (2001) (0)
Efficacy and Toxicity of FLAI-G-CSF and Mylotarg for Induction/Consolidation of AML Patients, Not Treatable with Conventional Chemotherapy. (2004) (0)
[Sprue syndrome and malignant lymphoma. 1 case]. (1970) (0)
PB2258 ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN MANAGEMENT OF MYELODYSPLASTIC SYNDROMES: RECAMDS TRIAL (2019) (0)
Correlation of JAK2 Mutation and PRV-1 and WT1 Transcript Amount in Myeloproliferative Disorders. (2005) (0)
ANTISENSE OLIGONUCLEOTIDES (2005) (0)
A simple Prognostic Scoring System for newly diagnosed acute leukaemia patients with normal karyotype: a retrospective analysis on 173 cases. (2009) (0)
Abstract 515: Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients (2017) (0)
Adult Triple Negative ACUTE Lymphoblastic Leukemia Genome Wide Characterization (2017) (0)
Abstract 541: Liquid biopsy for molecular characterization and monitoring in patients with metastatic colorectal cancer (2021) (0)
Gene Expression Profile in the CML Cell Line K562 Treated with SKI-606, a Dual Inhibitor of Src/Abl Kinase. (2005) (0)
9213 Induction and prolonged exposure to Rituximab in combination with Chlorambucil in untreated follicular lymphoma patients: a treatment with sustained response rate and a low toxicity profile (2009) (0)
Pcr-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation (2000) (0)
The Infection-Driven Production/Secretion of Inflammatory Cytokines By Circulating Monocytes of Myelofibrosis Is Defective and Is Reactivated after In VivoJAK1/2 Inhibition (2019) (0)
Supplementary Figure S5 (2012) (0)
4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party (2013) (0)
Current and future perspectives of maintenance therapy in multiple myeloma. (2020) (0)
ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY (2017) (0)
lymphoma biology 273 EXONIC MUTATIONS ARE COMMONLY FOUND IN PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA AND FAMILY MEMBERS OF WM PATIENTS WITH HYPER-IGM SYNDROME (2008) (0)
AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. (2022) (0)
From phenotypical investigation to RNA-sequencing for gene expression analysis: A workflow for single and pooled rare cells (2022) (0)
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) (2012) (0)
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients (2014) (0)
HLA molecular typing for selection of unrelated bone marrow donors (1994) (0)
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis (2014) (0)
BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era. (2012) (0)
DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma -Results from an EBMT Non Interventional Prospective Study (2010) (0)
Pegfilgrastim in Supportive Care of Hodgkin Lymphoma (2022) (0)
Abstract 3957: Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene (2015) (0)
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"]. (2014) (0)
9207 Efficacy of 90Yttrium-ibritumomab tiuxetan in extranodal marginal-zone lymphoma (2009) (0)
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. (2009) (0)
Age, Disease Status before Blinatumomab, MRD Negativity Obtainment, and Bridge to Transplant Influence Outcome in Patients with B‐ALL: A Single Center Experience: ALL‐089 (2018) (0)
Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up (2010) (0)
Abstract 2176: Whole-genome analysis of CNAs identifies four main evolution trajectories in multiple myeloma (MM) patients front-line treated with PI-based regimens (2018) (0)
High dose radioimmunotherapy with Zevalin(R) in refractory-resistant non Hodgkin's lymphoma: Preliminary results (2006) (0)
C-Myc Mediated Regulation of Multidrug Resistance Genes in Chronic Myeloid Leukaemia Cd34+ Cell Progenitors. (2009) (0)
Use of deep whole transcriptome sequencing in Philadelphia-positive acute lymphoblastic leukemia (ALL) to identify novel mutated genes and aberrant gene expression and alternative splicing profiles associated with disease progression. (2010) (0)
Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics (2018) (0)
Bitter Taste Receptors Are Expressed on Acute Myeloid Leukemia Cells and Their Activation Results in Quiescence Induction and Prevention of Migration (2017) (0)
A Multicentre Phase II Trial Testing Gemcitabine in the Treatment of Patients with Newly Diagnosed, Relapsed or Chemotherapy Resistant Mantle Cell Lymphoma: SAKK 36/03. (2007) (0)
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia (2014) (0)
P-012 Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide (2013) (0)
NETWORK APPROACHES FOR ANALYSIS AND MODELING OF THE HUMAN METABOLISM (2015) (0)
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia (2015) (0)
Direct sequencing on DRB allele-specific templates for the selection of unrelated bone marrow donors (1994) (0)
Study of Cancer-Prone Patients (2005) (0)
Genome-wide profiling of DNA copy number abnormalities in adult acute myeloid leukemia (AML) using high density single nucleotide polymorphism array (2008) (0)
The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL. (2007) (0)
Network integration of multi-tumour omics data suggests novel targeting strategies (2018) (0)
PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS (2019) (0)
Cancer Genes and Genomics c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD 34 þ Hematopoietic Progenitor Cells (2011) (0)
Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies (2018) (0)
SU11657, a FLT3-Targeted Tyrosine Kinase, Has Pro-Apoptotic Activity on Leukemia Cells In Vitro. (2005) (0)
Defects and Restores Protective Immunity Resection of Solid Tumors Reverses T Cell (2000) (0)
aggressive lymphoma 182 BENEFIT OF ANTI-VIRAL AND PNEUMOCYSTIS CARINII PROPHYLAXIS IN PATIENTS TREATED WITH R-CHOP (2008) (0)
MPN-184: Safety and Efficacy of Fedratinib, an Oral, Selective JAK2 Inhibitor, in Patients with Polycythemia Vera (PV) Resistant or Intolerant to Hydroxyurea: Results from a Phase II Dose-Ranging and Dose-Expansion Study (2020) (0)
Bronchial-associated lymphoid tissue (BALT) lymphoma: a retrospective analysis. (2006) (0)
CML WP the definition of complete cytogenetic response: a study of the GIMEMA for fluorescence in situ hybridization and chromosome banding analysis Chronic myeloid leukemia: a prospective comparison of interphase (2013) (0)
A255 2CdA and Rituximab Combination Treatment for Patients with Waldenström: Results of a Multicenter Study (2009) (0)
241 Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy (2011) (0)
In vitro and in vivo evaluation of human satellite muscle stem cells (2000) (0)
Cancer Therapy : Clinical Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and / or Erythropoietin Unresponsive Patients with Low / INT-1 – Risk Myelodysplastic Syndromes (2013) (0)
Abstract 1884: Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology (2012) (0)
Acknowledgement to referees (2006) (0)
9206 Long-term follow-up of follicular lymphoma (FL) patients receiving single agent rituximab at two different schedules in trial SAKK 35/98 (2009) (0)
Fall predictors in hospitalized patients living with cancer: a case–control study (2022) (0)
Non-Myeloablative Haploidentical Transplantation of Unmanipulated, G-CSF Mobilized Peripheral Blood Stem Cells with High Dose Post-Transplant Cyclophosphamide: Fast Engraftment, No Evidence of Graft Rejection and Low Incidence of Graft-Versus-Host-Disease (2014) (0)
Syndromes 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Valproic Acid at Therapeutic Plasma Levels May Increase (2009) (0)
Abstract 1772: Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) (2012) (0)
Obesity-related glomerulopathy: another nail in the coffin of the epidemic of end-stage renal disease (2007) (0)
Improved Detection of the KIT D816V Mutation Using a Real-Time PCR Assay Allows a Finer Recognition of Patients with Indolent Systemic Mastocytosis (2011) (0)
BCR-ABL1 -Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development, (2011) (0)
Abstract 4848: SNP array reveals a new deletion of JAK2 in AML patients (2015) (0)
High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance (2014) (0)
FOXO3 TRANSCRIPTION FACTOR IS DELOCALIZED AND INACTIVATED IN ACUTEMYELOID LEUKEMIA PATIENTS (2008) (0)
Adoptive Immunotherapy with Haploidentical Kir Ligand-Mismatched Natural Killer Cells In Elderly High Risk Acute Myeloid Leukemia Patients: Biological and Clinical Results of A Pilot Study (2010) (0)
“PCR fingerprinting” of HLA class I (A,B,C) genes (1994) (0)
Role of Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone (2021) (0)
Abstract 2243: Gene expression signature of aneuploidy in acute myeloid leukemia (2014) (0)
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia (2015) (0)
hCNT1 in Waldenström's macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) patients (pts): A possible predictive biomarker of 2-chloro-2`-deoxyadenosine (2-CDA) clinical activity. (2006) (0)
B497 Pathways Shared by t(4;14) and D13 positive MM Patients Impact Response to Velcade/Thalidomide/Dexamethasone (2009) (0)
Abstract 1873: Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplifiedMDM4and/or deletedp53 (2012) (0)
A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants. (2006) (0)
High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis. (2005) (0)
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE (2011) (0)
Abstract 5295: Impact of a multi-gene expression profile in predicting adjuvant trastuzumab outcome in HER2-positive breast cancer (2020) (0)
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study. (2016) (0)
CDKN2A/BAlterations Impair Prognosis in AdultBCR-ABL1– Positive Acute Lymphoblastic Leukemia Patients (2011) (0)
Direct and Coordinate Regulation of Multidrug Resistance Genes by the c-Myc Oncoprotein. (2006) (0)
Supplementary Figure Legends (2012) (0)
Down Regulation of TOPK, PBX3, SRPK, DDX21 and CLC Genes in Newly Diagnosed, Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. (2004) (0)
Abstract 784: Effect of co-mutations andFLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML) (2020) (0)
Abstract 3936: A branching evolution model at relapse characterizes multiple myeloma patients who responded to upfront combination therapy including new drugs (2017) (0)
The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein (2007) (0)
Abstract 4946: Bitter taste receptors system is expressed and functional in both HSCs and leukemic cells (2020) (0)
TARGETED THERAPY IN AML TREATMENT (2021) (0)
The Elevated Expression of FBP1 , a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients. (2010) (0)
P-296 Long-lasting hematologic response to azacitidine in myelodysplastic syndromes: Multicenter retrospective study of 36 patients (2013) (0)
What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study “Refoll” by the Fondazione Italiana Linfomi (FIL) On 548 Patients (2012) (0)
Molecular R emission A fter A llogeneic o r A utologous Transplantation o f H ematopoietic S tem C ells f or Multiple M yeloma (2000) (0)
Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia (2019) (0)
PET 215 QUANTITATIVE INTERIM PET IS MORE ACCURATE THAN QUALITATIVE ASSESSMENT IN PREDICTING OUTCOME IN DLBCL (2011) (0)
Abstract 1914: Acute myeloid leukemia cell and stem-progenitor cell behavior studied in mimetic bone marrow microenvironment (2019) (0)
Abstract 470: Chromosomal instability and bad prognosis both connote a multiple myeloma (MM) sub-type carrying 13qCN loss and 1qCN gain (2019) (0)
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. (2010) (0)
Detection of allele-specific gene expression on Next Generation Sequencing data (2012) (0)
Tyrosine Kinase Inhibitors (TKI) in Relapsed/Refractory (RR) Patients with FLT3‐ITD Positive Acute Myeloid Leukemia (AML) Confer Better Survival than Chemotherapy, Due to a Better Safety Profile: AML‐112 (2018) (0)
Abstract 90: A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia (2016) (0)
Erratum: ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma (Leukemia & Lymphoma (2003) vol. 44 (5) (801-806)) (2003) (0)
Does the percentage of host cells predict relapse in sex-mismatched allo-bmt? (1996) (0)
Abstract 3613: Lab-on-a-chip-based in-vitro functional profiling proves to be effective in predicting therapy outcome in AML patients (2018) (0)
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia (2017) (0)
To the editor: Relevance of cyclin D1 level in the pathogenesis of multiple myeloma (2003) (0)
A certi ﬁ ed plasmid reference material for the standardisation of BCR – ABL1 mRNA quanti ﬁ cation by real-time quantitative PCR (2015) (0)
Abstract 4619: PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients (2012) (0)
Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation in Renal Cell Carcinoma: The EIO Experience. (2005) (0)
BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (2010) (0)
Abstract 4632: Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain in Philadelphia-positive leukemias. (2013) (0)
Thyrosine phosphatase as modulators of in vitro resistance to STI571 (2002) (0)
Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated Multiple Myeloma: Old PLUS New Drugs in NOVEL Agents' Era (2021) (0)
Contents, Vol. 164, 1982 (1982) (0)
Indoleamine 2,3-Dioxygenase (IDO) Is Associated with High Incidence of Chemorefractory Disease in Acute Myeloid Leukemia (AML) Patients (2012) (0)
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors (2023) (0)
Identification of the Involvement of the Tyrosine Kinase C-Ros in the Pathogenesis of Chronic Myelomonocytic Leukemia (CMML) (2008) (0)
Biological therapy in elderly patients with acute myeloid leukemia (2023) (0)
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. (2014) (0)
C033 Quantification of phosphoinositidephospholipase C (PI-PLC) beta 1 gene promoter methylation predicts the responsiveness to azacitidine in myelodysplastic syndromes (2009) (0)
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML). (2005) (0)
PS1461 FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES (2019) (0)
Evaluation of prognostic role of inflammatory index in glioblastoma multiforme patients undergoing to concomitant radio-chemotherapy. (2019) (0)
Abstract 4433: A Phase I study of two dosing regimens of oral AS703569, an inhibitor of aurora kinase and other kinases, in patients with hematologic malignancies (2010) (0)
Abstract 3884: Gene expression profiling and copy number alterations of circulating clonotypic B cells of multiple myeloma newly diagnosed patients reveals pathways potentially involved in the development and in the disease persistence (2014) (0)
Efficacy of 90yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma, (2011) (0)
IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease (2021) (0)
Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano (2008) (0)
The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia. (2009) (0)
High-Resolution Genomic Profiling of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) Identified Novel Recurrent Copy Number Variations Involved in Both Pathogenesis and Resistance to Tyrosine Kinase Inhibitors. (2007) (0)
Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. (2009) (0)
Systemic Mastocytosis. A GIMEMA Multicenter Survey. (2006) (0)
ASSESSMENT OF THE INTERLABORATORY VARIABILITY AND ROBUSTNESS OF JAK2V617F MUTATION ASSAYS: A STANDARDIZATION STUDY INVOLVING A CONSORTIUM OF 19 ITALIAN LABORATORIES (2016) (0)
A More Mature Immunophenotypic Make-up of Multiple Myeloma Clone(s) at Diagnosis Correlates With a Higher Genomic Instability (2017) (0)
DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN REVEALS A FREQUENCY OF 35INS INSERTION/TRUNCATION HIGHER THAN EXPECTED (2013) (0)
Diapositive Fanconi Anemia (2013) (0)
P033 The Akt/mTOR signal transduction pathway is activated in high risk myelodysplastic syndromes and influences cell survival and proliferation (2007) (0)
A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice (2020) (0)
Abstract 2539: Antiapoptotic gene expression signature reveals a combined talk to prevent apoptosis: A model to choose the proper BH-3 mimetic drug (2018) (0)
Abstract 6163: Fusion landscape in acute leukemias: A submerged world of not routinely characterized transcripts (2023) (0)
Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia (2015) (0)
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications (2017) (0)
SETD2 loss of function as a new marker of advanced disease in systemic mastocytosis: biological and clinical implications (2020) (0)
The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors. (2007) (0)
Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment. (2007) (0)
Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan. (2007) (0)
Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study (2008) (0)
HRAS expression predicts Lenvatinib responsiveness in human primary gastroenteropancreatic neuroendocrine tumor cells. (2022) (0)
An integrated model to improve medication reconciliation in oncology: the PROF-1 trial (Preprint) (2021) (0)
The Quantitative Assessment of WT1 Allows To Distinguish between Primary and Secondary or Reactive Hypereosinophilia. (2005) (0)
Darbepoetin Alpha For the Treatment of Anemia in Systemic Mastocytosis (2019) (0)
Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol. (2004) (0)
Abstract 1872: Pharmacological inhibition of WIP1 sensitizes AML cells to MDM2 inhibitors (2018) (0)
Abstract 705: Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). (2013) (0)
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications (2017) (0)
Nephro-ileal conduit subcutaneous stent: an alternative to percutaneous nephrostomy. (2006) (0)
PS1461 FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES (2019) (0)
167 Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response (2011) (0)
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. (2014) (0)
Screening of Bcr-Abl Transcripts in Philadelphia Negative Essential Thrombocythemia (2000) (0)
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 (2013) (0)
The Quantitative Assessment of WT1 Allows To Distinguish between Primary and Secondary or Reactive Hypereosinophilia. (2005) (0)
leukemia patients reaction" for the detection of BCR/ABL transcript in chronic myeloid A new method of "in-cell reverse transcriptase-polymerase chain (2011) (0)
Abstract 4507: New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients (2016) (0)
MDS-227: Digital PCR for Sensitive Detection and Accurate Quantification of KIT D816V Allele Burden in Patients with Suspected Systemic Mastocytosis (2020) (0)
ONCORELIEF - A Digital Guardian Angel Supported by an AI System to Improve Cancer Patient Quality of Life, Wellbeing and Health Outcomes: Protocol for a Pilot Study (Preprint) (2023) (0)
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. (2005) (0)
Italian cooperative study on idiopathic hypereosinophilic syndrome (HES): FIP1-L1/PDGFRA rearrangement can be effectively treated with imatinib (2003) (0)
Disease status Initial Response , Best MRD after MRD after CR Site of Survival Status (2004) (0)
NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia. (2006) (0)
ACCURACY AND PRECISION OF RESULTS AFTER IMPLEMENTATION OF INTERNATIONALSCALE TO EVALUATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIAPATIENTS COORDINATED ON BEHALF OF GIMEMA-CML WP (2009) (0)
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT). (2016) (0)
RASGRP1/APTX Ratio Is a Strong Biomarker of Clinical Response and Survival In AML Patients Treated with Tipifarnib: A Phase I-II Preliminary Results (2010) (0)
Evaluation of mezlocillin in treatment of acute and chronic prostatitis. (1989) (0)
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain (2013) (0)
Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma Cisplatin-refractory,HER2/neu-expressing germ-cell cancer: Induction of remission by the monoclonal antibody Trastiizumab (2005) (0)
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience (2011) (0)
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients. (2009) (0)
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib. (2010) (0)
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders (2023) (0)
Genome wide analysis of Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) reveals a recurring deletion of VPREB1 gene which affects B-cell differentiation (2014) (0)
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) (2016) (0)
Systemic Mastocytosis. A GIMEMA Multicenter Survey. (2006) (0)
C025 Role of lipid signaling pathways in the response to erythropoietin in low risk MDS patients (2009) (0)
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia. (2016) (0)
Abstract 656: Distinct pattern of alterations in TP53 mutated/deleted and wild-type high risk acute myeloid leukemia (AML) patients: Identification of new "targetable" genes/pathways (2018) (0)
Abstract 2143: High-Resolution Molecular Karyotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Identifies Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes (2010) (0)
High doses of recombinant erythropoietin alfa for myelodysplastic syndromes: High incidence of responses in patients with low pre-treatment serum erythropoietin concentrations. (2004) (0)
PS1020 SNP ARRAY REVEALS A NEW DELETION OF JAK2 IN AML PATIENTS (2019) (0)
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted (2023) (0)
A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, and Other CD123-Positive Hematologic Malignancies (2019) (0)
Mitomycin C in the treatment of superficial bladder neoplasm. (1988) (0)
Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study (2008) (0)
Abstract 2451: Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia (2017) (0)
PF169 LONG-TERM INHIBITION OF CHK1/CHK2 KINASES MODIFY ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINE RESPONSE TO DNA DAMAGING AGENTS (2019) (0)
Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study (2016) (0)
Abstract 5448: Pharmacogenetics of drug transporters may be useful to identify chronic myeloid leukemia patients who are less likely to achieve molecular responses to imatinib: Implications for treatment optimization in the era of new tyrosine kinase inhibitors (2011) (0)
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis (2015) (0)
MPN-204: Midostaurin Synergizes with Nilotinib and Dasatinib Restoring SETD2 Expression and Activity in Advanced Systemic Mastocytosis (2020) (0)
Abstract 709: Estrogen and androgen receptor inhibitors: Unexpected allies in the fight against COVID-19 (2021) (0)
Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO) (2022) (0)
Frequent Elevation of Akt Kinase Phosphorylation in Mononuclear Cells from High-Risk Myelodysplastic Syndrome Patients. (2005) (0)
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol (2022) (0)
P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS (2022) (0)
96 OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH >30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY (2015) (0)
PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS (2019) (0)
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration (2017) (0)
Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy. (2010) (0)
Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics. (2006) (0)
positive chronic eosinophilic leukemia - FIP1L1-PDGFRA responses and achievement of complete molecular remission in Low-dose imatinib mesylate leads to rapid induction of major molecular (2013) (0)
MPN-180: A Novel Mechanism of Action of Midostaurin in Systemic Mastocytosis: Beyond KIT Inhibition (2021) (0)
chronic myeloid leukemia: 2013 European LeukemiaNet recommendations for the management of (2013) (0)
Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. (2013) (0)
Haematological Support: Progenitor Cell Collection and Processing (1998) (0)
ALL-073: Inotuzumab Ozogamicin (IO) and Donor Lymphocyte Infusion (DLI) are a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) (2020) (0)
Acute Myeloid Leukemia-Derived Dendritic Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-dioxygenase. (2006) (0)
Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP (2008) (0)
Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?. (2006) (0)
LAL0201-B protocol of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) acute lymphoblastic leukemia without additional chemotherapy: results positive patients with - survival in elderly Philadelphia chromosome Imatinib plus steroids induces complete remissions and prolonged (2013) (0)
responders : a study of complete cytogenetic α Chronic myeloid leukemia and interferon- (2013) (0)
Abstract 2907: A metaproteomic approach to study the host-microbiota interaction in cancer tissue (2021) (0)
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. (2007) (0)
A novel denaturing high-performance liquid chromatography (D-HPLC) based method for kit mutation screening of patients (pts) with systemic mastocytosis (SM) (2007) (0)
PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS (2019) (0)
Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia. (2010) (0)
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing (2014) (0)
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) (2007) (0)
Abstract 4835: A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 (2015) (0)
Randomized trial of a 3-fold dose intensification of Ifosfamide, Carboplatin, Etoposide chemotherapy for the treatment of small cell lung cancer: P1-221 (2007) (0)
Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way (2019) (0)
Whole-Transcriptome Sequencing of a Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time of Progression to Blast Crisis (BC). (2009) (0)
positive chronic eosinophilic leukemia - FIP1L1-PDGFRA responses and achievement of complete molecular remission in Low-dose imatinib mesylate leads to rapid induction of major molecular (2013) (0)
Efficacy and Toxicity of FLAI-G-CSF and Mylotarg for Induction/Consolidation of AML Patients, Not Treatable with Conventional Chemotherapy. (2004) (0)
Insuline-Like Growth Factor 1 Is over Expressed in Multiple Myeloma Plasma Cells and Regulates the Expression of the Insuline-Like Growth Factor 1 Receptor. (2005) (0)
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients (2010) (0)
Abstract B03: Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome. (2015) (0)
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia (2015) (0)
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy (2016) (0)
Correction: Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia (2022) (0)
Graft-Versus-Lymphoma Effect in Hodgkin’s Disease: A Possible Role in Maintaining a Disease Control. (2005) (0)
240 Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients (2011) (0)
Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia (2022) (0)
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTICTARGET (2013) (0)
Erratum: Early stage gastric diffuse large B-cell lymphomas: Results of a randomised trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy (Leukemia and Lymphoma (2009) 50:6 (925-931)) (2009) (0)
A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups (2018) (0)
Deep Molecular Response to Nilotinib as First-Line Treatment of Bcr-Abl+ Chronic Myeloid Leukemia (2015) (0)
Mature Circulating Endothelial Cells and Progenitors in Patients with Chronic Gvhd (2011) (0)
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) (2016) (0)
The Alternate Activation of Hedgehog Pathway, Either in CD138+ or in CD138-CD19+ Multiple Myeloma Primary Cells, Impacts on Disease Outcome (2015) (0)
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis (2016) (0)
A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients (2010) (0)
PS931 ADULT TRIPLE NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA FUSION DETECTION: CHALLENGING AIM FOR PH- ALTERNATIVE THERAPIES (2019) (0)
elderly patients with chronic myeloid leukemia Effects and outcome of a policy of intermittent imatinib treatment in (2013) (0)
Inhibition of cfu-gm growth by idarubicinol containing plasma samples obtained from poor prognosis lymphoma patients treated with 3-days infusion idarubicin (1998) (0)
Abstract 246: Genome-wide screening for dominant modifiers in Drosophila identified new genes involved in BCR-ABL signaling and chronic myeloid leukemia (CML) progression (2010) (0)
IgG Antibodies against Human Cytomegalovirus Late Protein UL94 in the Pathogenesis of Scleroderma-Like Skin Lesions in Chronic Graft Versus Host Disease (2008) (0)
Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity. (2009) (0)
PF251 GILTERITINIB PROLONGS SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML WHO HAVE COMMON AML CO-MUTATIONS OR A HIGH FLT3-ITD ALLELIC RATIO (2019) (0)
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene (2015) (0)
Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile. (2009) (0)
Abstract PS10-19: Gene expression profile in HER2-positive breast cancer to predict outcome in patients treated with adjuvant trastuzumab (2021) (0)
Unravel Inter-Tumor and Intra-Tumor Heterogeneity of Digitally Sorted Single Hodgkin and Reed Sternberg Cells Using Genome-Wide Copy Number Profiling (2018) (0)
Mine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs (2016) (0)
EFFICACY AND SAFETY OF DASATINIB IN CML/ALL PH1+ IMATINIB RESISTANT PATIENTS IN A COMPASSIONATE USE PROGRAM (2008) (0)
Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT. (2010) (0)
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia (2016) (0)
Bitter Taste Receptors System Is Expressed and Functional in Both HSCs and Leukemic Cells (2018) (0)
Genomic Instability and Activation Of The DNA Damage Response Pathway Is An Independent Predictor Of Poor Prognosis, Is Associated With MYC Expression and Is a Promising Target For Therapy In Diffuse Large B Cell Lymphoma (2013) (0)
Abstract 2682: Extrafollicular high CD163/CD8 ratio is associated with progression of disease within 24 months in follicular lymphoma patients (2020) (0)
Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients. (2006) (0)
Modulation of Tryptophan Catabolism by Acute Myeloid Leukemia Cells Acts as a General Mechanism of Immune Tolerance Via the Induction of T Regulatory Cells. (2007) (0)
Abstract P2-13-44: HDAC6 is an unfavorable prognostic factor in HER2-positive breast cancer patients treated with adjuvant trastuzumab (2022) (0)
FLT-3 Activity and Its Response to Drugs Can Be Determined in AML Blast Cells by FLT-3 Phosphorylation Status Using Flow Cytometry. (2006) (0)
Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial (2008) (0)
Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. A Study by the GIMEMA Working Party on CML. On Behalf of GWP on CML. (2005) (0)
Bronchial-Associated Lymphoid Tissue (BALT) Lymphoma: A Multicenter Retrospective Analysis. (2004) (0)
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. (2009) (0)
Two Novel WT-1 Derived Peptides Induce CD4+ peptide–specific T Cell Proliferation in Patients with Myelodysplastic Syndrome (MDS) (2008) (0)
Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies (2007) (0)
MM-382: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents' Era (2020) (0)
[Thrombosis of the renal veins in the adult]. (1987) (0)
Induction Intensified Regimens Including Fludarabine or Mylotarg for Acute Myeloid Leukemia Patients: Comparison by Response and Follow-up. (2008) (0)
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy (2018) (0)
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS (2010) (0)
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study (2016) (0)
CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients. (2009) (0)
Outcomes in Patients With FLT3-Mutated R/R AML Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib Versus Salvage Chemotherapy. (2022) (0)
PF560 A MATURATION INDEX DEFINES NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH ADVANCED IMMUNOPHENOTYPIC AND MOLECULAR DIFFERENTIATION PROFILES ASSOCIATED WITH POOR PROGNOSIS (2019) (0)
Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma. (2020) (0)
Targeting Lon Protease Activity Promotes Growth Inhibition and Apoptosis in Acute Myeloid Leukemia Cell Lines (2014) (0)
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells (2015) (0)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) AMIEE.JACKSON, a MICHAELMIAN, c,d CHRISTINAKALPADAKIS, e GERASSIMOSA.PANGALIS, f ANASTASIOSSTATHIS, g ELENAPORRO, g ANNARITACONCONI, h (2015) (0)
Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party. (2006) (0)
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients (2012) (0)
myeloid leukemia in patients 70 years or older care, including hydroxyurea, in the treatment of newly diagnosed acute A randomized phase 3 study of tipifarnib compared with best supportive (2011) (0)
Abstract 5022: The selection of TP53 sub-clonal variants over time identifies MM patients with adverse clinical outcome (2016) (0)
Corrigendum: Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells (2021) (0)
PB2288 BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW ARM IN NOVEL AGENTS’ WORLD (2019) (0)
Lymphoid Subpopulations and Safety Profile in Untreated-Follicular Lymphoma Receiving Rituximab Monotherapy as Induction and Maintenance Therapy. (2006) (0)
Pelvic myeloid sarcoma: a multidisciplinary approach. (2017) (0)
A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment (2008) (0)
[Bronchus carcinoid tumor in the Tessin canton, retrospective analysis of 13 years and literature review]. (1996) (0)
Phase I-II Trial of Adoptive Immunotherapy with Haploidentical KIR Ligand-Mismatched Natural Killer Cells in High Risk Acute Myeloblastic Leukemia Patients. (2007) (0)
Association between transporters genotype and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the tops trial. (2009) (0)
Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia (2013) (0)
Arterial Thrombotic Events in CML Patients Treated with First-Line Nilotinib: Incidence, Management and Impact on the Long Term Outcome — a Gimema CML WP Analysis (2017) (0)
Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma (2021) (0)
Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (2020) (0)
Abstract 1521: High-throughput molecular profiling of Multiple Myeloma clonotypic CD19+ B cells highlights pathways potentially involved in the disease endurance (2015) (0)
cells Interleukin-9 stimulates the proliferation of human myeloid leukemic (2011) (0)
Abstract 2236: Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study (2011) (0)
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. (2017) (0)
High levels of tumor load reduction after intensive chemotherapy favorably affect the prognosis of BCR/ABL+ ALL adult patients receiving Imatinib Mesylate alone as a post-consolidation treatment according to the Italian GIMEMA LAL 0201/A protocol (2006) (0)
Epigenetic regulation of UNCX, a novel homeobox transcription factor gene activated in acute myeloid leukemia (2015) (0)
Abstract 1600: Molecular Characterization ofPAX5alterations in AdultBCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) (2010) (0)
Abstract 4671: Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients (2017) (0)
Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy (2018) (0)
Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics. (2006) (0)
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients (2013) (0)
Therapy-related acute leukemia associated with involvement of 11 q 23 after high grade non-Hodgkin lymphoma (2005) (0)
CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis (2021) (0)
Multidrug Resistance Gene (MDR1) Polymorphisms May Serve as Predictors of Resistance to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients. (2007) (0)
P040: LINE-1 REVERSE TRANSCRIPTASE ACTIVITY IN HODGKIN LYMPHOMA CELLS (2022) (0)
FoxO Transcription Factor Is Delocalized in CML Patients by Bcr-Abl Induced PI3K/AKT Activation and IKK Pathway and Can Be Reactivated by Imatinib Treatment. (2007) (0)
A specific ‘leukemia diagnostic panels’ based on selection of novel relevant biomarkers for leukemiadignosis, prognosis and therapeutic decision making (2015) (0)
Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the ‘NEXT-IN-CML' Study (2017) (0)
PB1691 CDC20 IS A NOVEL POTENTIAL THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA (2019) (0)
Author response for "REAL‐WORD EXPERIENCE WITH DECITABINE AS A FIRST‐LINE TREATMENT IN 306 ELDERLY ACUTE MYELOID LEUKAEMIA PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY" (2019) (0)
JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome (2015) (0)
Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1 . (2007) (0)
Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement (2011) (0)
Abstract 2951: Gene expression profiling identifies new adult "triple-negative" acute lymphoblastic leukemia (ALL) subgroups (2018) (0)
Reply to Tattevin and Camus (2006) (0)
The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells (2019) (0)
Down Regulation of TOPK, PBX3, SRPK, DDX21 and CLC Genes in Newly Diagnosed, Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. (2004) (0)
122 Chromosome 5Q31-specific DNA probe to detect intertitial long arm deletions of chromosome (1997) (0)
Abstract 3749: Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. (2013) (0)
A pharmacogenetic approach towards personalised anti-cancer drug use (2010) (0)
Key Immune Cell Subsets Are Dysregulated in Patients with Myelofibrosis (2014) (0)
Pyrrolo[1,2-B][1,2,5] benzodiazepines (PBTDs) Compounds Induce Apoptosis in Chronic Myeloid Leukaemia Cells from Patients at Onset, Imatinib and Second Generation TK Inhibitors (Dasatinib, Nilotinib) Resistant. (2006) (0)
Carboplatin (CBDCA) and paclitaxel (TAX) as induction chemotherapy in stage IIIA–IIIB in non small cell lung cancer (NSCLC) (1999) (0)
Signals of the Inflammatory Microenvironment Promote a Mutation-Associated Functional Dysregulation of the Circulating Megakaryocyte Progenitors of Myelofibrosis (2016) (0)
Abstract 3788: Antigen presentation by MHC-I molecule and immune escape in acute myeloid leukemia with high burden of genomic aberrations (2018) (0)
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS (2012) (0)
ABL populations by ultra-deep sequencing of the resistant − Unraveling the complexity of tyrosine kinase inhibitor (2013) (0)
Abstract 1804: Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience (2010) (0)
Cytokeratin and mammaglobin as tumor markers in patients with high risk breast cancer (2000) (0)
Typing of HLA-DQA by polymerase chain reaction, heteroduplexes and single strand conformational polymorphism analysis (1994) (0)
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report (2017) (0)
Leukemia cutis in a Ph+ ALL patient treated with ponatinib. (2018) (0)
Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile. (2009) (0)
The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors. (2007) (0)
Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy. (2010) (0)
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year (2011) (0)
PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS (2019) (0)
Long Term Efficacy of Percutaneous Vertebroplasty in Multiple Myeloma (MM) Patients: Experience of the “Gruppo Ematologico Di Romagna” (GER) (2011) (0)
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma (2012) (0)
Topical oral GM-CSF to prevent oral mucositis in patients (PTS) receiving high dose chemotherapy (HDCT) (1999) (0)
Erratum: Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers (Annals of Oncology (2001) vol. 12 (7) (987-990)) (2001) (0)
Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case report. (2013) (0)
Abstract 3886: Clec12a: A new AML stem cell-associated antigen (2014) (0)
PF197 A NEW CLASSIFICATION OF ACUTE MYELOID LEUKEMIA BASED ON INTEGRATED GENOMICS AND METABOLOMICS (2019) (0)
Primary Female Genital Lymphoma: Prognostic and Therapeutic Considerations (2008) (0)
The Non Receptor Transmembrane Tyrosine Kinase STYK1 Represents a Novel Lymphocyte Marker, Whose Expression Is Deregulated in Leukemia, and a Potential Molecular Druggable Target (2008) (0)
Abstract 3415: SIRT regulates the molecular interaction between c-MYC and HIF-1α in multiple myeloma. (2013) (0)
Abstract 333: Development of a biomimetic 3D scaffold to study breast cancer bone metastasis (2020) (0)
Abstract 2964: Pharmacological inhibition of WIP1 by GSK2830371 sensitizes AML cells to MDM2 inhibitor Nutlin-3a (2019) (0)
Contents Vol. 111, 2004 (2004) (0)
PS997 A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1 (2019) (0)
The Re-Activation of FoxO3 Transcription Factor in Acute Myeloid Leukaemia Is Responsible for the Induction of a Quiescent Status of Leukaemic Progenitor Cells. (2008) (0)
How I manage frontline transplant-eligible multiple myeloma in Italy (2020) (0)
Abstract 368: Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy (2016) (0)
OVERALL POOR PROGNOSIS OF LEUKEMIC LYMPHO- PROLIFERATION WITH MANTLE CELL PHENOTYPE MANTLE CELL LYMPHOMA: CHROMOSOMAL ABERRA- TIONS, PROLIFERATON AND CYCLIN D1 TRANSCRIPTS IN RELATION TO CLINCIAL OUTCOME GENE EXPRESSION TO IDENTIFY NEW GENES IN MANTLE CELL (2005) (0)
Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient. (2009) (0)
A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM) (2014) (0)
Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells (2015) (0)
IKZF1 deletion patterns in adult ALL patients. (2012) (0)
Ubiquitin-proteasome system is a sensitive target in Ph + leukemia (2009) (0)
Induction Intensified Regimens Including Fludarabine or Mylotarg for Acute Myeloid Leukemia Patients: Comparison by Response and Follow-up. (2008) (0)
The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles (2018) (0)
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium (2015) (0)
Prognostic Relevance of t(4;14) and Expression of FGFR3 and TACC3 in Newly Diagnosed Patients with Multiple Myeloma. (2005) (0)
Improved detection of the C-KIT D816V mutation using allele-specific arms real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. (2013) (0)
High doses of recombinant erythropoietin alfa for myelodysplastic syndromes: High incidence of responses in patients with low pre-treatment serum erythropoietin concentrations. (2004) (0)
Abstract 4248: A long tail of sub-clonal TP53 mutations emerged by ultra-deep sequencing of newly diagnosed multiple myeloma (MM) (2015) (0)
PF288 POPULATION PHARMACOKINETIC (POPPK) AND CONCENTRATION-QTC ANALYSIS OF QUIZARTINIB IN PATIENTS (PTS) WITH FLT3-ITD–POSITIVE RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) (2019) (0)
Correlation of RASGRP1/APTX ratio with clinical response and survival in AML patients treated with tipifarnib-bortezomib combination. (2010) (0)
Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allotransplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients (2018) (0)
Patterns of relapse after bone marrow transplantation for chronic myeloid leukaemia. (1991) (0)
Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability. (2008) (0)
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors (2014) (0)
mplications of BCR-ABL 1 kinase domain-mediated resistance n chronic myeloid leukemia (2013) (0)
Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML (2020) (0)
Presence of human papillomavirus DNA in breast cancer patients: SERUM and tissue analysis. (2020) (0)
Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma (2010) (0)
CML with E8A2 BCR-ABL Fusion: The Fourth Breakpoint Cluster Region?. (2004) (0)
Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin’s Lymphoma (HL): A Single Centre Experience. (2007) (0)
Exposure–response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer (2021) (0)
P90 Does the mobilization regimen influence peripheral blood stem cell (PBSC) tumor contamination in early breast cancer patients that undergo high dose chemotherapy? A comparison of chemotherapy plus G-CSF vs G-CSF mobilized PBSC (1998) (0)
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia (2014) (0)
Diapositive Li-Fraumeni Syndrome (2013) (0)
Abstract 2140: “3c-up” a new adult Philadelphia negative acute lymphoblastic leukemia subgroup: Novel molecular markers (2019) (0)
Evaluation of the GeneXpert Assay for the Monitoring of BCR-ABL Transcript Levels In Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of a Comparison with the Manual and Traditional Manual TaqMan RQ-PCR Assay (2010) (0)
Chronic Myeloid LeukemiaProgress in Hematology (2005) (0)
PF733 COMBINED ORAL ANALGESIA AND ANXIOLYSIS FOR PAIN ASSOCIATED WITH BONE MARROW ASPIRATION AND BIOPSY (2019) (0)
Monozygotic Twins with Childhood ALL Demonstrate Prenatal Origin of the Philadelphia Chromosome and Post-Natal Ikaros Deletion. (2009) (0)
Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party (2014) (0)
Stable hematological, cytogenetic and molecular remission in a splenectomised CML patient 22 years after diagnosis: analysis of cytokine production by PBMC subpopulations (1998) (0)
PS928 “3C-UP” A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP: NOVEL MOLECULAR MARKERS (2019) (0)
201 Cytogenetics to monitor disease outcome after allo-BMT in patients with myelodysplastic syndrome (MDS) (1997) (0)
Abstract 651: Whole transcriptome sequencing of Philadelphia positive acute lymphoblastic leukemia (ALL) by RNA-seq: an exhaustive overview of novel point mutations, gene expression and alternative splicing profiles (2010) (0)
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients (2015) (0)
Abstract CT312: Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience (2014) (0)
Cellular Reprogramming Erases Aberrant DNA Methylation and the Malignant Phenotype in Chronic Myeloid Leukemia (2014) (0)
Chemotherapy-Dependent ATP Release from Leukemia Dying Cells Induces Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells (2016) (0)
What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia? (2020) (0)
IMATINIB FIRST-LINE WITH SWITCH TO 2ND GENERATION TYROSINE KINASE INHIBITORS IN CASE OF FAILURE OR TOXICITY: REAL-LIFE DATA FROM A POPULATION-BASED REGISTRY OF BCR-ABL1+CML PATIENTS (2016) (0)
PF622 CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (2019) (0)
Multiple molecular mechanism may account for resistance to imatinib in resistant cell lines (2007) (0)
The italian mastocytosis registry: an update focused on histopathological findings (2011) (0)
Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetan. (2009) (0)
Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia (2021) (0)
Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted (2018) (0)
Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML. (2004) (0)
WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. (2010) (0)
Culture conditions that stimulate expansion of normal hematopoietic progenitors from chronic myelogenous leukemia marrow (1997) (0)
90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients. (2009) (0)
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS (2013) (0)
Severe neuropathy in a patient with Waldenstrom disease: From a challenging diagnosis to clinical improvement by innovative therapy (2006) (0)
acute myeloid leukemia patients ligand-mismatched natural killer cells after infusion in elderly high risk Successful transfer of alloreactive haploidentical KIR (2011) (0)
Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients. (2009) (0)
A der(1)t(1;21)(p36.3;q22) in a Patient with Acute Myelogenous Leukemia M2 (2010) (0)
Prognostic role of inflammatory index in head and neck squamous-cell carcinoma patients in first line chemotherapy. (2018) (0)
CML-206: ReSETting SETD2/H3K36Me3 Deficiency as a New Therapeutic Strategy in Blast Crisis Chronic Myeloid Leukemia Patients (2020) (0)
Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party (2010) (0)
Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib (2015) (0)
Abstract 3608: HIF-1α inhibition blocks the cross talk between multiple myeloma plasmacells and tumour microenvironment (2014) (0)
MM-389: Pomalidomide-Dexamethasone in the Management of Heavily Pre-Treated Multiple Myeloma (2020) (0)
A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study (2010) (0)
Abstract 309: Whole-transcriptome sequencing in chronic myeloid leukemia reveals novel gene mutations that may be associated with disease pathogenesis and progression (2011) (0)
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, induces cell cycle arrest, apoptosis, and synergizes with chemotherapeutic drugs in acute myelogenous leukemia cells-a novel therapeutic approach for leukemia. (2008) (0)
Rituximab Reduces Anti-UL94 and Anti-NAG-2 Antibodies Titer and Is Effective against Skin-Chronic Graft Versus Host Disease Resembling Scleroderma. (2009) (0)
Title : Targeting CDK 6 and BCL 2 exploits the “ MYB addiction ” of Ph + acute lymphoblastic leukemia (2017) (0)
Abstract 4694: The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma (2012) (0)
Abstract 4700: Clinical outcome of T-acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL): the Bologna experience. (2013) (0)
[Clinico-hematological aspects in medullary metastases of non-lymphomatous solid tumors]. (1980) (0)
Variable but Consistent Pattern of Meningioma 1 Gene (MN1) Expression in Different Genetic Subsets of Acute Myelogenous Leukaemia and Its Potential Use as Marker for Minimal Residual Disease Detection. (2007) (0)
Erythropoiesis Stimulating Agents (ESAS) in Supportive Care of Low-Risk Myelodysplastic Syndromes: Recamds Registry FINAL Results (2021) (0)
Abstract 3472: Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels (2017) (0)
An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival (2015) (0)
Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients (2020) (0)
Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents (2021) (0)
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis (2014) (0)
TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA (2016) (0)
Hedgehog Pathway Over Expression Identifies Myeloma Patients With Worse Prognosis (2015) (0)
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis. (2022) (0)
In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors (2019) (0)
Abstract 310:BCR-ABL1transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method (2011) (0)
CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients. (2006) (0)
High rate of complete hematological response in elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of nilotinib and imatinib: a GIMEMA clinical trial LAL 1408. (2015) (0)
A313 R2CdA in Waldenström (WM): Do Polymorphism and Gene Expression Have Predictive Roles in Response? (2009) (0)
Poster: MM-409: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pre-Treated Multiple Myeloma: Old/New in the Novel Agents’ Era (2021) (0)
Refractory Chronic Lymphocytic Leukemia (2009) (0)
Ponatinib vs Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) ALL: PhALLCON Study (2019) (0)
PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG (2010) (0)
A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants. (2006) (0)
Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Imatinib: Introducing the Concept of Confirmed Molecular Response. (2007) (0)
Abstract 3957: Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene (2015) (0)
Idarubicin containing regimen in mm: preliminary results of pilot study of a modified “tandem” transplant program (2001) (0)
IDENTIFICATION OF A MOLECULAR SIGNATURE PREDICTIVE OF REFRACTORINESS IN ACUTE MYELOID LEUKEMIA (2005) (0)
Abstract 1179: Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. (2013) (0)
Abstract 3387: The pliancy of plasma cell differentiation status conceals a gradient of chromosomal instability in newly diagnosed multiple myeloma patients (2018) (0)
Abstract 570:Tp53mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome (2014) (0)
Nuclear Inositide Signalling: Role of PI‐PLCbeta1 in MDS and AML (2010) (0)
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia (2021) (0)
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients (2010) (0)
Abstract 1138: First Application of Whole-Transcriptome Sequencing to a High-Risk Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time of Disease Progression to Blast Crisis (BC) (2010) (0)
Abstract 5255: Breast cancer subtype classification using a multi-gene expression profile (2019) (0)
Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph plus Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML (2010) (0)
ROLE OF THE AURORA KINASE A AXIS IN IMATINIB RESISTANCE OF CHRONIC MYELOID LEUKEMIA CD34+ PROGENITORS (2016) (0)
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL). (2012) (0)
Low pegfilgrastim serum concentration at 11th day allows chemotherapy intensification in advanced Hodgkin’s disease patients (2005) (0)
Ubiquitin-proteasome system is a sensitive target in Ph + leukemia (2009) (0)
Abstract 4906: TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome (2015) (0)
The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair (2012) (0)
"Metronomic" versus maximum tolerable dose chemotherapy in preclinical lymphoma models (2000) (0)
Bone marrow of a patient with acute non-lymphoblastic leukaemia associated with the t(1;7)(p11;p11) chromosomal translocation. (2002) (0)
Response and outcomes to nilotinib at 24 months in patients with imatinib-resistant chronic myeloid leukemia in chronic phase and accelerated phase with and without BCR-ABL mutations (2010) (0)
Abstract #3871: Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia (2009) (0)
PB2324 LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE (2019) (0)
A Study of the Binding Mode and the In Vitro Activity of the Protein Tyrosine Kinase Inhibitor SKI-606 in the BCR-ABL Positive Cells. (2006) (0)
Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up (2010) (0)
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia (2015) (0)
The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study) (2008) (0)
PB1726 DOUBLE FLUDARABINE-BASED INDUCTION AND INFECTIVE RISK: THE BOLOGNA EXPERIENCE. (2019) (0)
A COMBINED APPROACH TO DETECT RARE FUSION EVENTS IN ACUTE MYELOID LEUKEMIA (2016) (0)
379 A first in human phase I study of the proteasome inhibitor CEP-18770 in patients (pts) with advanced solid tumors, non-Hodgkin's lymphomas (NHL) and multiple myeloma (MM) (2010) (0)
RALE051: a novel established cell line of sporadic Burkitt lymphoma (2018) (0)
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells (2022) (0)
Abstract 2082: PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience. (2013) (0)
AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA) (2019) (0)
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) (2014) (0)
Antiproliferative Effects of Tyrosine Kinase (STI 571) and Farnesyl Transferase Inhibitors (R115777 and SCH66336) on Acute Leukemia Human Tumor Cell Lines. (2005) (0)
Erratum: The publisher would like to apologize on behalf of the authors. Since publication of the ORIGINAL ARTICLE: CLINICAL (Leukemia and Lymphoma (2009) 50(6) 925-931 (2010) (0)
An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia (2019) (0)
Abstract 3582: Chromothripsis in AML patients: A new mechanism of cancer initiation and progression (2016) (0)
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients (2012) (0)
Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol (2020) (0)
Abstract 2207: A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). (2013) (0)
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL). (2011) (0)
A novel denaturing high-performance liquid chromatography (D-HPLC) based method for kit mutation screening of patients (pts) with systemic mastocytosis (SM) (2007) (0)
Abstract 2237: Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience (2011) (0)
Whole Transcriptome Sequencing of a Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) with “Next Generation Sequencing” Technology Revealed Novel Point Mutations Associated with Disease-Progression. (2009) (0)
Subject Index Vol. 111, 2004 (2004) (0)
Underdiagnosed systemic mastocytosis: The role of flow cytometry (2007) (0)
Five-year follow-up results of imatinib 400 mg in late chronic phase chronic myeloid leukemia (CML) patients (2007) (0)
Imatinib 400 mg in Early Chronic Phase CML: Results of a Multicentric, Prospective Non Academical Observational Study (by the GIMEMA CML Working Party). (2006) (0)
In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants (2014) (0)
Abstract LB-105:In vitroandin vivosingle-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia (2014) (0)
PRE-FINAL ANALYSIS OF THE PHASE II EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PH+ CML PATIENTS WITH STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) – EUDRACT NUMBER 2007-005102-42, CLINICALTRIALS.GOV NCT 00858806. (2010) (0)
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events (2012) (0)
BROMODOMAIN INHIBITION TARGETS ACUTE MYELOID LEUKEMIA CELLS UNDER HYPOXIA AND ALTERS THE REGULATION OF KEAP1/NRF2 PATHWAY AT TRANSCRIPTIONAL, TRANSLATIONAL AND POST-TRANSLATIONAL LEVEL (2018) (0)
Abstract 260: Bromodomain and extra-terminal motif proteins regulate linear and circular PVT1 in acute myeloid leukemia cells under normoxia and hypoxia (2020) (0)
Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients. (2009) (0)
RASGRP1/APTX Ratio Is a Strong Biomarker of Clinical Response and Survival In AML Patients Treated with Tipifarnib: A Phase I-II Preliminary Results (2010) (0)
Abstract 4051: Loss of nuclear beta catenin, following chibby enforced expression, activates endoplasmic reticulum stress in cells expressing the BCR-ABL1 fusion gene of chronic myeloid leukemia. (2013) (0)
phase Ii Study For The Evaluation Of Feasibility, Activity And Safety Of Bendamustine And Ofatumumab In Combination In Marginal Zone B-cell Lymphomas (mzl) : 198 (2015) (0)
[Carcinoma of the pancreas with hypokalemic watery diarrhea (Verner-Morrison syndrome). Presentation of a case and review of literature)]. (1979) (0)
inhibitors resistance or intolerance to imatinib and other tyrosine kinase Bosutinib safety and management of toxicity in leukemia patients with (2014) (0)
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 (2011) (0)
Development of a Genetic Tool Based on BCR-ABL Transgenic Drosophila Melanogaster for Identification of Genes Involved in CML Progression and Drug Testing. (2007) (0)
Tumor Control Achieved Despite Loss of Chimaerism in Renal Cell Carcinoma (RCC) Following Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Case Report. (2005) (0)
NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia. (2006) (0)
Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between the NPM leukemic mutant and NF-κB in AML carrying NPM1 mutations (2010) (0)
REPLY TO GUNSILIUS ET AL (2000) (0)
Fungal and Bacterial Infections in Acute Myeloid Leukemia Patients Treated with Induction Regimens Including Fludarabine: A Retrospective Analysis of 224 Cases. (2007) (0)
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience (2012) (0)
A novel framework for chimeric transcript detection based on accurate gene fusion model (2011) (0)
CARDIOVASCULAR EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH NILOTINIB FIRST-LINE: AN ANALISYS OF THE GIMEMA CML WP (2015) (0)
Deranged MicroRNA 16-2 Expression Contributes to Erythropoiesis in Polycythemia Vera. (2009) (0)
Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL) (2010) (0)
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia (2013) (0)
MDS-502 Supportive Care in Low-Risk Myelodysplastic Syndromes: Role of Erythropoiesis Stimulating Agents (ESAs). (2022) (0)
SNP detection by RNA-seq (2013) (0)
Advancing precision medicine through multi-omics: An integrated approach to tumor profiling (2015) (0)
Aging Significantly Drives Decision Making and Outcome in Immune Thrombocytopenia Patients: A Monocentre Study on 508 Patients (2017) (0)
Abstract 473: Higher levels of genomic complexity correlates with an advanced plasma cell differentiation status in newly diagnosed multiple myeloma patients (2019) (0)
Italian cooperative study on idiopathic hypereosinophilic syndrome (HES): FIP1-L1/PDGFRA rearrangement can be effectively treated with imatinib (2003) (0)
Disease status Initial Response , Best MRD after MRD after CR Site of Survival Status (2004) (0)
[Massive thrombosis of the left atrium: Case report and review of the literature (author's transl)]. (1977) (0)
MDS-391: Role of Erythropoiesis-Stimulating Agents (ESAs) in Supportive Care of Low-Risk Myelodysplastic Syndromes (2020) (0)
Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509 (2011) (0)
The italian mastocytosis registry: an update focused on histopathological findings (2011) (0)
leukemia Molecular response to Imatinib in late chronic phase chronic myeloid (2012) (0)
Multiple myeloma in 2020: state of the art. (2020) (0)
Quantitative Molecular Expression of the Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia Cells as a Possible Marker for Minimal Residual Disease Detection. (2007) (0)
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients (2011) (0)
A critical comparison of Sokal, Euro, and Eutos risk scores in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. (2015) (0)
LONG-TERM FOLLOW-UP AND SAFETY OF DASATINIB IN CML/ALL PH1+IMATINIB RESISTANT PATIENTS IN A COMPASSIONATE USEPROGRAM (2009) (0)
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing (2014) (0)
Abstract 5595: Impact of p53 impaired function on outcomes of multiple myeloma patients carrying deleted TP53 and/or amplified MDM4 (2014) (0)
Azacytidine: first therapeutic opportunity for myelodysplastic syndromes (2009) (0)
Identiﬁcation and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1 –positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMAAL WP) (2009) (0)
Abstract 294: Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia (2017) (0)
In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors (2019) (0)
Autologous stem cell transplantation in multiple myeloma. (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Giovanni Martinelli?

Giovanni Martinelli is affiliated with the following schools:

Giovanni Martinelli's Academic­Influence.com Rankings

Giovanni Martinelli's Degrees

Similar Degrees You Can Earn

Why Is Giovanni Martinelli Influential?

Giovanni Martinelli's Published Works

Published Works

What Schools Are Affiliated With Giovanni Martinelli?

Giovanni Martinelli's AcademicInfluence.com Rankings